Review

Fucoidans in Nanomedicine

Lucas Chollet 1,2,3,†, Pierre Saboural 1,2,‡, Cédric Chauvierre 1,2, Jean-Noël Villemin 3, Didier Letourneur 1,2 and Frédéric Chaubet 1,2,*

1 Inserm, U1148, LVTS, University Paris Diderot, X Bichat Hospital, F-75877 Paris, France; lucas.chollet@algues-et-mer.com (L.C.); pierre.saboural@univ-paris13.fr (P.S.); cedric.chauvierre@inserm.fr (C.C.); didier.letourneur@inserm.fr (D.L.)
2 Galilée Institute, University Paris 13, Sorbonne Paris Cité, F-93430 Villetaneuse, France
3 Algues & Mer, Kernigou, F-29242 Ouessant, France; jn.villemin@algues-et-mer.com
* Correspondence: frederic.chaubet@univ-paris13.fr; Tel.: +33-1-4940-4090; Fax: +33-1-4940-3008
† These authors contributed equally to this work.

Academic Editor: Paola Laurienzo
Received: 17 June 2016; Accepted: 21 July 2016; Published: 29 July 2016

Abstract: Fucoidans are widespread cost-effective sulfated marine polysaccharides which have raised interest in the scientific community over last decades for their wide spectrum of bioactivities. Unsurprisingly, nanomedicine has grasped these compounds to develop innovative therapeutic and diagnostic nanosystems. The applications of fucoidans in nanomedicine as imaging agents, drug carriers or for their intrinsic properties are reviewed here after a short presentation of the main structural data and biological properties of fucoidans. The origin and the physicochemical specifications of fucoidans are summarized in order to discuss the strategy of fucoidan-containing nanosystems in Human health. Currently, there is a need for reproducible, well characterized fucoidan fractions to ensure significant progress.

Keywords: fucoidans; nanomedicine; sulfated polysaccharides; nanosystems; drug delivery; imaging agent; tissue regeneration

1. Introduction

Fucoidans are abundant cost-effective marine polysaccharides which exhibit a wide spectrum of biological activities with potential clinical applications. For more than half a century, extensive works have been published about the activities of these molecules; some of the most recent reviews are listed in Table 1. Recently, nanomedicine began to incorporate the use of fucoidans especially in the domains of cancer, regenerative medicine, and cardiovascular diseases, fields in which nanotechnologies are making progress every day. Since 2005, reports on fucoidans in nanomedicine have increased to represent about 7% of the overall works in 2014 related to both topics (Figure 1).

This review focuses on the progress at the interface of fucoidans and nanomedicine in the perspective of development of new diagnostic and therapeutic tools for human use. In the first part, fucoidans and their biological properties are briefly presented and in the second part the main studies of fucoidans with regard to developments in nanomedicine are given. In the last part, we discuss the relevance of these studies in light of the structural data of fucoidans and we question an appropriate strategy for the development of fucoidans for human applications.
2. What Are Fucoidans?

Fucoidans belong to a large family of marine sulfated polysaccharides named fucans mainly constituted of sulfated L-fucose, which include also ascophyllans (xylofucoglycuronan and xylofucomonuranuronan) and sargassans (glycuronofucogalactan) [1,2]. Fucoidans were first discovered in 1913 by Kylin in brown algae: Ascophyllum nodosum, Fucus vesiculosus, Laminaria digitata and Laminaria saccharina [3]. Since then, fucoidans have been identified in 70 more species of brown algae (Phaeophyceae) [4–12], in the body wall of some marine invertebrates such as sea cucumber (Holothuroidea), and in the egg jelly coat of sea urchins (Echinoidea) [4,13,14].

Fucoidans are contained in the extracellular matrix (ECM) of brown algae’s cell walls [1]. Considering the eco-physiological influences (alga species, location and season of harvesting, the position on the intertidal zone, etc.) on the composition of fucoidans, they are implicated in the ionic and osmotic regulation and in the mechanical support of the cell wall [2,15]. Thus, the algae which have been most exposed to drying seem to contain the highest fucoidan content. In sea urchin, fucoidans play a role in the fertilization process since they are found in the surrounding coating of the female gamete (zona pellucida) and participate in the species-specific acrosome reaction [16,17]. In sea cucumber, fucoidans could be involved in the structural support of the body wall in the saline environment, as for algae [18].

The chemical composition of fucoidans is extremely variable depending on eco-physiological parameters. The first structure was elucidated in 1950 by Conchie and Percival from a fucoidan extracted from Fucus vesiculosus [19]. Kloareg et al. determined that fucoidans were composed of 50%–90% of L-fucose, 35%–45% of sulfate and less than 8% of uronic acid with a linear backbone based on an α(1→2)-glycosidic linkage of O-4 sulfated L-fucose and some oses like galactose, mannose, xylose, and glucose [1,2]. In 1993, Patankar et al. published a revised structure of a commercial fucoidan from F. vesiculosus: mainly an α(1→3)-L-fucose linear backbone with sulfate substitution at O-4 and some α-L-fucose branched at O-4 or O-2 [20]. Thereafter, studies on fucoidans’ structure evidenced different repeating units for highly purified fucoidan fractions from different species [21–28]. Structures are based on an α(1→3)-L-fucose backbone with some alternating α(1→4) linkages. The sulfation patterns are variable but sulfate groups are mainly found at O-2 and O-4 [29,30]. Fucoidans extracted from marine animals have a more regular chemical structure (Figure 2).
with organic solvents (e.g., acetone, toluene, etc.) from the fresh materials provides dried extracts.

Although it is now widely admitted that the term “fucoidan” refers to a sulfated-polymer, it is still not possible to speak of a single compound; “fucoidans” should always be used as a general term. These bottom-up approaches could be used to synthesize a wide range of FF with well-defined structures, improving the knowledge in the structure-biological activity relationships for these molecules. Although, tremendous progress in glycobioLOGY and glycomedicine has driven the development in oligosaccharide synthesis, industrial preparation of tailor-made FF remains still hard to achieve due to low overall yields and the

Figure 2. Repeating chemical structures of some fucoidans from brown algae (A) Chorda filum [28]; (B) Ascophyllum nodosum, Fucus vesiculosus, and Fucus evanescens [22,23,31] and from marine invertebrates: sea cucumber (Holothuriacea) (C) Ludwigothuria grisea [29]; (D) Strongylocentrotus droebachiensis [17], and (E) Strongylocentrotus franciscanus [30].
time needed to complete the process. Interestingly, there is currently no standard method to obtain reproducible bioactive well defined FF either from top-down or bottom-up strategies.

3. Biological Properties of Fucoidans

The interest of the scientific community in fucoidans and their low molecular weight fractions (i.e., below 30 kDa) is mainly driven by the wide spectrum of biological activities evidenced from their discovery up to now. Table 1 gathers the main biological effects reported and the identified targets. Over the last decades, new functions of polysaccharides and more specifically low molecular weight (LMW) fractions have attracted the interest of scientists for their ability to act in a wide variety of biological processes [47]. Structural variations such as degrees of substitution with chemical groups (in particular carboxylates, acetates or sulfates) are implicated in biological responses [48,49] and their activities are often attributed to their negative charges and sulfation degrees rather than to any specific carbohydrate structure as described for heparin [50]. Low molecular weight fractions from mammalian, glycosaminoglycans (GAGs) and more particularly low molecular weight-GAGs from heparin, heparan sulfate, hyaluronate, and chondroitin sulfate are implicated in a wide variety of biological processes as cofactors for growth factor, cytokines and chemokines production, tumorigenesis, signaling molecules in response to infection or other cellular damage, regulator of blood coagulation, and assisting viral and bacterial infections [51–53], the most active compounds being neutral or anionic structures partially acetylated or sulfated.

So far, multiple targets have been identified in blood and tissues to explain the biological activities of fucoidans. The anticoagulant activity, one of the most studied with reference to heparin, can be explained by the interactions of fucoidans towards natural thrombin inhibitors, serpins antithrombin, and heparin cofactor II, enhancing their activity [11]. P- and L-selectins, membrane proteins which play a role in the leukocyte rolling and extravasation process in vascular inflammatory response, have been reported and studied as the main targets in the anti-inflammatory activity of fucoidans [54,55]. Likewise, the inhibition of complement activation through classical and alternative pathways, also responsible for fucoidans anti-inflammatory activity, occurs by inhibiting formation or function of several complement’s enzymes such as C4, C4b,2a, C3, and C3b,Bb [56].

| Biological Properties          | Identified Targets                                      | References                     |
|--------------------------------|--------------------------------------------------------|--------------------------------|
| Anticoagulant/anti-thrombotic   | Antithrombin, heparin cofactor II                       | [11,34,57–59]                  |
| Anti-complement                 | C4, C4b,2a, C3, and C3b,Bb                             | [56,59,60]                     |
| Anti-viral                      | CD4                                                    | [61–68]                        |
| Anti-inflammatory               | P-selectin and L-selectin                              | [54,55,59,69–76]               |
| Angiogenic effect               | VEGFs, bFGF, FGF-2, α6, β1, and PECAM-1 integrin subunits | [10,11,54,59,77–87]           |
| Anti-cancer                     | Caspases-3, -8 and -9, MAPK and their inhibitors, HIF-1 | [29,88–110]                    |
| Anti-diabetic                   | α-glucosidase, α-amylase                              | [111–118]                      |
| Immune potentiating             | NK cells, T-cells, dendritic cells                     | [119–123]                      |
| Antioxidant                     |                                                        | [124–141]                      |

Antiviral activity is ensured by the binding of fucoidans to the CD4 glycoprotein on T lymphocytes, an essential immunoglobulin in the infection process of host cells by the viruses [67]. Fucoidans, especially fucoidans with high sulfation content, inhibit α-glucosidase and α-amylase, two digestive enzymes, increasing or interrupting the absorption delay of glucose. The most sulfated fractions have an inhibitory effect more pronounced than the less sulfated ones and electrostatic interactions are likely involved [112,113]. In tissues, fucoidans have an effect on several enzymes responsible for mitosis or cellular apoptosis such as caspases-3, -8 and -9 or mitogen-activated protein kinase (MAPK) and their inhibitors [91,92,102], enhancing or silencing these factors in opposite ways in cancer cells or healthy cells (protective effect). Furthermore, LMW fucoidan fractions inhibit the accumulation of hypoxia-inducible factors-1 (HIF-1) which promote tumor angiogenesis in cancer cells [99].

The biological activities of fucoidans seem mainly modulated by their molecular weight and their sulfate content, which, as previously stated depend on the starting material and the method
of preparation. One of the most striking examples is the anti/pro-angiogenic activity. Pomin et al. evidenced that fucoidans of various origins exhibit an anti-angiogenic activity due to their ability to interfere with vascular endothelial growth factors (VEGFs) and basic fibroblast growth factor (FGF-2) [11]. However, Matou et al. showed the pro-angiogenic effect of fucoidans, also extracted from *Ascophyllum nodosum*, by enhancing the expression of α6, β1, and PECAM-1 integrin subunits on the surface of endothelial cells, resulting in an increase of FGF-2-induced angiogenesis [85]. Nifantiev et al. reviewed numerous studies on the angiogenic activities of fucoidans from different brown algae to highlight structure-activity relationships. They could only conclude that FF from *Ascophyllum nodosum* with MW over 30 kDa exhibited anti-angiogenic activity whereas FF with MW lower than 30 kDa exhibited pro-angiogenic activity [10].

Fucoidans exhibit several bioactivities against a wide spectrum of pathological situations with a remarkable absence of adverse effects. On one hand, it is now widely accepted that levels of L-fucose and sulfate as well as the molecular weight are major structural parameters whose variation affect the biological properties. On the other hand, each algae species produces its own type of fucoidan whose composition also depends on the conditions of obtaining. Pharmaceutical grade fucoidans with well-defined molecular weight distributions and thoroughly defined chemical compositions are now needed. It is necessary to obtain proper structure-activity relationships in order to select the most relevant FF for human clinical trials.

4. Fucoidans in Nanomedicine

Nanomedicine, also defined as nanotechnology in the biomedical field, has gained considerably in interest in the last decade. Nanosystems, such as, in a non-exhaustive way, nanoparticles, polymeric carriers, nanotubes, micelles, and liposomes have size-dependent properties and nanometer-scale dimensions which play important roles in biological systems. For half a century, they have been developed for therapeutic and diagnostic purposes and more recently have found tremendous applications in regenerative medicine with the development of nanostructured biocompatible scaffolds for cell organization and proliferation [142]. Moreover, nanotheranostics or theranostic nanomedicines have also been developed combining diagnosis and therapy to monitor both the release and the bioavailability of the drug at the proper pathological site [143]. The major interest of nanomedicine remains for drug delivery and personalized medicine defined as “the right drug to the right patient at the right moment” [144,145]. Most of these new biomedical tools are currently employed for treatments via oral or parenteral administration to fight cancer, iron deficiency or multiple sclerosis as examples [142]. Lovrić et al. reviewed the marketed products and those with the greatest potential [142].

Sulfated polysaccharides, especially fucoidans have been included in nanosystems for diagnostic, drug delivery, and tissue engineering [146,147]. Fucoidans have also been used as stabilizers of nanoparticles (NPs) [148–152] or to study the behavior of the aqueous suspension of chitosan/fucoidan-based NPs [153–155]. These works will not be detailed here since this review is dedicated to FF-containing nanosystems with direct applications to diagnosis and therapy. Table 2 assembles such applications, mainly with fucoidan-containing nanoparticles (FNPs), and the most relevant are explained in the following text. Table 3 indicates the origin and physicochemical data of FF used in these 31 reported studies.

Table 2. Applications of fucoidan-containing nanosystems in nanomedicine.

| Application                  | References   |
|-----------------------------|--------------|
| Imaging agent               | [156–162]    |
| Protein delivery            | [163–167]    |
| Small drug delivery         | [168–176]    |
| Anti-coagulant              | [177,178]    |
| Gene delivery               | [179,180]    |
| Regenerative medicine       | [181–186]    |
Table 3. Features of the fucoidan fractions used in nanomedicine related studies.

| Study | Objective | Origin of Fucoidans | Molecular Weight | Sulfate Content * | Other Data | Remarks |
|-------|-----------|---------------------|------------------|------------------|------------|---------|
| Bonnard et al. [157,159] | P-selectin tagging FMPs for SPECT imaging | F. vesiculosus | 57 kDa/23 kDa | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Changotade et al. [185] | Pretreatment of bone tissue substitute | - | - | - | - | |
| Da Silva et al. [178] | FNPs preparation for therapeutic purposes | F. vesiculosus | - | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Huang et al. [169] | Gentamicin controlled release | F. vesiculosus | - | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Huang et al. [174] | Curcumin controlled release | F. vesiculosus | - | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Huang et al. [165] | FGF-2 controlled release with FNPs | F. vesiculosus | 80 kDa | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Huang et al. [166] | SDF-1 controlled release with FNPs | F. vesiculosus | 80 kDa | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Jeong et al. [182] | Design of a scaffold for bone tissue regeneration | - | - | - | - | |
| Jin et al. [186] | Design of a scaffold for bone tissue regeneration | U. pinnatifida | - | - | - | Commercial fucoidans from Haewon Biotech Company |
| Kimura et al. [172] | Evaluation of cytotoxic effects of FNPs | C. okamuranus | 2–10 kDa | - | - | Fucoidans extracted and purified by the authors |
| Kurosaki et al. [180] | DNA delivery with FMPs | - | - | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Lee et al. [171] | DOX controlled release with FNPs | F. vesiculosus | - | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Lee et al. [187] | Electrospun mats for Tissue engineering | U. pinnatifida | - | 34.2% | 62.12% total polysaccharide | Commercial fucoidans from Haewon Biotech Company |
| Li et al. [162] | P-selectin tagging FMPs for PET imaging | - | - | - | - | Commercial fucoidans from Sigma Aldrich Company |
| Lira et al. [188] | Preparation and evaluation of FNPs | S. cymosum | 53 kDa | - | - | Fucoidans extracted and purified by the authors |
Table 3. Cont.

| Study                        | Objective                                      | Origin of Fucoidans | Molecular Weight | Sulfate Content * | Other Data | Remarks                                                   |
|------------------------------|------------------------------------------------|---------------------|------------------|-------------------|------------|-----------------------------------------------------------|
| Lowe et al. [183]            | Design of a scaffold for bone tissue regeneration | *F. vesiculosus*    | -                | -                 | -          | Commercial fucoidans from Sigma Aldrich Company           |
| Nakamura et al. [164]        | FGF-2 controlled release                        | *K. crassifolia*    | -                | -                 | -          | Fucoidans extracted and purified by the authors           |
| Park et al. [167]            | ALA controlled release with FMNs                | -                   | -                | -                 | -          | Commercial fucoidans from Haewon Biotech Company          |
| Pinheiro et al. [176]        | PLL controlled release                           | *F. vesiculosus*    | 57.26 kDa        | -                 | 40.2% Fuc, 2.98% Xyl, 0.55% Man, 3.6% Gal, 9.17% Ur.Ac, 0.11% Rha, 0.21% Glu | Commercial fucoidans from Sigma Aldrich Company |
| Puvaneswary et al. [184]     | Design of a scaffold for bone tissue regeneration | *F. vesiculosus*    | -                | -                 | -          | Commercial fucoidans from Sigma Aldrich Company           |
| Sezer et al. [179]           | DNA delivery with FMPs                          | *F. vesiculosus*    | 80 kDa           | -                 | -          | Commercial fucoidans from Sigma Aldrich Company           |
| Sezer et al. [189,190]       | FNPs for dermal burns treatment                 | *F. vesiculosus*    | 80 kDa           | -                 | -          | Commercial fucoidans from Sigma Aldrich Company           |
| Suzuki et al. [191]          | P-selectin targeting FNPs for MRI imaging       | *A. nodosum*        | 8 kDa            | 27%               | 45% l-fucose, 25% D-glucuronic acid | Commercial fucoidans from Algues et Mer Company |
| Venkatesan et al. [181]      | Design of a scaffold for bone tissue regeneration | -                   | -                | -                 | -          |                                                          |
| Wu et al. [175]              | Berberine controlled release                    | -                   | 80 kDa           | -                 | -          | Commercial fucoidans from NOVA Pharma & Liposome Biotech Company |
| Yu et al. [168]              | Berberine controlled release                    | *L. japonica*       | -                | 24.3%             | 3.5% carboxyl groups | Commercial fucoidans from NOVA Pharma & Liposome Biotech Company |
| Yu et al. [96]               | Oversulfated FF release via oral route           | *F. vesiculosus*    | 80 kDa           | 41.7%             | -          | Commercial fucoidans from NOVA Pharma & Liposome Biotech Company |

* g/100 g.
4.1. Fucoidans in Therapeutic Nanosystems

In 2006, Sezer and Akbuga were the first to design FNPs named “fucospheres” from mixtures of fucoidan and chitosan for drug delivery purposes [163]. Two years later, they demonstrated the efficacy of fucospheres from the same origin over chitosan-based NPs in the treatment of dermal burns in rabbits [189,190]. The fucospheres size ranged from 300 nm to 1000 nm with surface charges from +6 to +26 mV and were tested in vitro on freshly excised chicken back skin. Then, in vivo tests were conducted on rabbits with the most efficient FNPs and the authors observed the highest level of wound healing after 21 days in groups treated with fucospheres as compared to those treated with chitosan microspheres or FF solution. FF has been found to accelerate the healing effects on dermal burns when coupled with chitosan which is able to re-epithelise and encourage fibroblast migration to the burn sites.

At the same time, Nakamura et al. designed FF/chitosan microparticles loaded with fibroblast growth factor 2 (FGF-2) [164]. FF was purified from the starting material with calcium chloride. FGF-2-loaded microparticles were then subcutaneously injected and neovascularization was observed in ischemic tissue in a mice model.

In 2013, another group synthesized FGF-2-loaded spherical nanoparticles, by dripping a mixture of FF and FGF-2 into a solution of chitosan under stirring [165]. This study evaluated the release of the growth factor in vitro and its effect on the differentiation of PC12 neural progenitor cells evidencing a synergistic activity on nerve cell growth as compared to FGF-2 in solution alone.

Chitosan/FF/tripolyphosphate NPs were synthesized and loaded with stromal cell-derived factor-1 (SDF-1) as a therapeutic agent for tissue regeneration by Huang et al. [166]. FNPs were efficient in protecting SDF-1 from inactivation by proteolysis, heat, and pH and the released SDF-1 was able to improve the proliferation and the migration of rat mesenchymal stem cells for up to seven days.

In 2009, Sezer et al. also used fucospheres to encapsulate and to deliver plasmid DNA encoding GM-GSF [179]. The diameter ranged from 150 to 400 nm with a zeta potential from 8.3 mV to 17.1 mV depending on the chitosan molecular weight. The encapsulation capacity was evaluated between 84% and 95% depending on the chitosan molecular weight and the amount of plasmid added to the loading solution. Once encapsulated in fucospheres, the plasmid was released in vitro and its integrity was validated. No tests on cells or in vivo experiments have been published yet.

The same year, Kurosaki et al. developed a ternary complex FF/pDNA/Polyethylenimine [180]. The complexes had 72 nm mean diameter and –27 mV zeta potential. FNPs were tested on B16-F10 mouse melanoma cells to assess the uptake and the transfection efficiency in vitro. They showed no cytotoxicity as compared to the pDNA/PEI NPs after 2 h of incubation and a concentration of 10 mg/mL of pDNA. However, when added to the B16-F10 cells, FNPs showed significantly lower uptakes and gene expression as compared to fucoidan-free NPs.

Pinheiro et al. synthesized chitosan/fucoidan multilayer nanocapsules (FNCs) as a vector for the controlled release of poly-L-lysine (PLL), a polypeptide exhibiting strong antimicrobial activity, as a drug model [176]. Ten chitosan/fucoidan layers were formed over a polystyrene core removed after synthesis by repeated dipping in THF. The encapsulation of PLL was better when performed during the formation of the NCs. The encapsulation efficiency and the loading capacity of FNCs strongly depended on the initial PLL concentration used, with the highest values obtained at a PLL concentration of 1 mg mL⁻¹. PLL release from the FNCs was found to be pH-dependent with a maximum at pH 2 due to a weakening of the nanocapsules interpolyelectrolyte structure and suggested a peculiar release behavior. Due to the bioactivities and non-cytotoxicity of FF and chitosan, FNCs were envisaged by the authors as nanocarriers to protect and release bioactive compounds for food and pharmaceutical applications.

Yu et al. prepared chitosan-based beads embedded with FNPs for oral delivery of berberine, an antimicrobial agent used to inhibit the growth of bacteria in the digestive system [168]. The NPs/beads complexes inhibited the growth of Staphylococcus aureus and Escherichia coli in simulated gastric or intestinal fluids. Complexes also demonstrated a delayed drug release over
24 h in simulated gastric fluid, which could be suitable for later drug delivery to the small intestine. Another group developed chitosan/fucoidan-taurine conjugate NPs to deliver berberine via the oral route to treat defective intestinal epithelial tight junction barrier [175]. The release of berberine was found to be pH-dependent with higher release at intestinal pH (7.4) than gastric pH (2.0). In vitro, the authors demonstrated the protective effect of the FNPs on Caco-2 cell monolayer, as a model of the epithelial barrier, co-cultured with LPS-treated RAW 264.7 cells. The results suggested the utility of such FNPs in allowing local delivery of berberine on bacterial-derived lipopolysaccharides intestinal epithelia tight junction disruption, to restore barrier function in inflammatory and injured intestinal epithelium.

Huang et al. developed antioxidant FNPs for antibiotic delivery to the lungs [169]. The use of FF was explained by their antioxidant and anti-inflammatory properties in order to treat pulmonary allergic inflammations. FNPs size ranged from 230 nm to 250 nm and their compactness and stability were maintained for 25 days. They exhibited highly potent antioxidant effects by scavenging 1,1-diphenyl-2-picrylhydrazyl (DPPH), and reducing the concentration of intracellular reactive oxygen species (ROS) as well as superoxide anion in stimulated macrophages. As an antibiotic model drug, Gentamicin (GM) was used for controlled release assays in vitro. The FNPs released 99% of GM over 72 h after an initial 10 h burst release. They were considered as potential carriers for antibiotics delivery to the lungs in the case of pulmonary infections and to be useful to treat airway inflammatory diseases.

In order to deliver drugs with low solubility and high pH sensitivity, Huang et al. developed O-carboxymethyl chitosan/fucoidan NPs to increase cellular curcumin uptake (Cur), a polyphenolic compound exhibiting several biological activities such as antitumor, antioxidant, inhibiting cardiovascular diseases, and inducing apoptosis [174]. Cur-loaded FNPs (Cur-FNPs) had an average diameter of 270 nm and encapsulated 92.8% of the drug. Cur-FNPs considerably decreased the cytotoxicity of Cur to mouse fibroblasts cells (L929), were stable in the gastric environment (pH 2.5), and allowed the release of Cur in the simulated intestinal environment (pH 7.4). The cellular uptake of Cur-FNPs was evaluated using Caco-2 cells. An internalization of Cur-FNPs by the cells through energy-dependent endocytic pathways was observed making O-carboxymethyl chitosan/fucoidan NPs potential carriers in oral delivery systems.

Park et al. prepared core/shell microparticles by co-axial electro-spray drying [167]. FF was mixed with the antioxidant α-lipoic acid (ALA). The size of the microparticles ranged from 5.4 to 8.4 µm. FF and ALA were detected within the core, and the chitosan within the shell of the microparticles. These composite microparticles were able to gel by water uptake and then swelled, contrary to the physical mixture of FF and chitosan; the swelling was found to depend on pH with a decrease for pH values higher than 7. In the same way, decreasing the chitosan/FF ratio lowered the swelling of the hydrogel. Finally, the release behavior of ALA from the gel was validated in vitro in different pH media by applying different electric potentials, inducing the drug release. The cumulative amounts of released ALA were quantified over 48 h to conclude that not only a declining concentration gradient occurred but also that the physical gelation between FF and chitosan over time reduced the diffusion of ALA, resulting in a unique release behavior with possible applications in drug delivery systems, wound healing dressings or scaffolds.

Lee et al. combined the immunotherapeutic activity of an acetylated FF with self-organized nanospheres loaded with doxorubicin (DOX) [171]. FNPs reached a 71% loading efficiency and the release followed a first order kinetic. FNPs were incubated for 24 h with RAW-264.7 macrophages, then tumor necrosis factor α (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression levels were measured. TNF-α expression was improved by a factor of 1.13 and GM-CSF by a factor of 1.86 as compared to unloaded FNPs and free DOX in a multidrug resistant cell model. Finally, these FNPs were considered as good candidates for combined immunotherapy and chemotherapy.

In the development of an oral drug delivery system, chitosan was found to modulate the opening of the tight junctions of epithelial cells [177]. Da Silva et al. prepared fucospheres with anti-coagulant properties for oral delivery by a nanocoacervation [178]. The size of FNPs ranged from 198 to 352 nm
mean diameter and their zeta potential was measured between 35 and 53 mV. The anticoagulant activity of aqueous suspensions of these fucospheres was not found significantly different from that of FF and FNPs did not show cytotoxicity for Caco-2 cells up to 1 mg/mL after 3 h of incubation.

At the same time, Yu et al. designed fucospheres to release an over sulfated FF via the oral route [96]. FNPs were able to go through a Caco-2 cell monolayer by opening the tight junctions. Eventually, it was found that released over sulfated FF had a higher anti-angiogenic activity than native FF.

By mixing FF and soybean lecithin in a homogenizer, Kimura et al. prepared unilamellar liposomes mixed with FF (FFL) of 100 nm and compared their cytotoxic effects with the native FF on osteosarcoma in vitro and in vivo [172]. FFL were found to reduce the viability of human osteosarcoma cell line 143B in vitro with a maximum inhibition for 2 mg/mL of liposome and 72 h of incubation. In addition, FFL were more potent than FF to induce apoptosis in cells. Mice were inoculated with murine osteosarcoma LM8 tumor cells and treated with FFL or native FF. FFL induced a reduction of the volume and the weight of the tumor compared to FF-treated mice.

Lira et al. compared in 2011 the cytotoxicity on macrophages and fibroblast murine cell lines of FNPs obtained by coating poly(isobutylcyanoacrylate) (PIBCA) with a blend of dextran and FF with two methods, a redox radical emulsion polymerization (RREP) and an anionic emulsion polymerization (AEP) [188]. FNPs prepared by the former were four times less toxic than those prepared by the latter. The authors also observed that FNPs obtained by RREP were not stable with a ratio FF/dextran of over 25, while FNPs obtained by AEP were stable in suspension with 100% FF as coating material.

4.2. Fucoidans in Diagnostic Nanosystems

Nanosystems for diagnosis must be blood compatible and non-toxic at concentrations sufficient for recording relevant images of the region of interest. To a large extent, sulfated polysaccharides could meet these criteria as vectors of imaging markers. Among these, fucoidans have been evidenced as good candidates to image atherothrombosis in vivo [156,191], and still awaited are studies evidencing their usefulness for cancer imaging.

In 2011, Rouzet et al. showed the direct complexation of $^{99m}$Tc by a commercial FF allowing SPECT imaging of thrombosis and heart ischemia thanks to the interaction of FF with P-selectin overexpressed by activated platelet and activated endothelium [158]. Biodistribution studies of $^{99m}$Tc-labelled FF in rat by SPECT imaging evidenced a urinary elimination and a moderate liver and spleen uptake which decreased with a fraction obtained from treatment with calcium ions of FF [160].

With the same FF, Suzuki et al. evidenced the capacity of superparamagnetic FNPs to detect in vivo the intraluminal thrombus of abdominal aortic aneurysm in a rat model with a 4.7 T MR imager [191]. FNPs were obtained by linking FF to the carboxymethyl-dextran shell of Ultrasmall Superparamagnetic Iron oxide (USPIO). FNPs had a size of 50 nm and a zeta-potential of $-14.3$ mV. Surface Plasmon Resonance experiments evidenced an affinity of the FNPs for P-selectin in 1–10 nM range compared to NPs coated only with carboxymethyl-dextran, in accordance with previous work of Bachelet et al. [55]. Other in vitro studies showed the capacity of these FNPs to bind to activated human platelets [156].

Bonnard et al. developed polysaccharide-based NPs from dextran and pullulan cross-linked with sodium trimetaphosphate (STMP) in a water-in-oil emulsion [157,161]. FF was added to the emulsion to provide NPs functionalized with fucoidans (FNPs) with an average hydrodynamic diameter of 358 nm and a zeta-potential of $-16$ mV. MPFs contained about 1.6% (w/w) of FF and energy dispersive X-ray (EDX) spectrum showed the presence of FF at the surface of the particles. The interaction of MPFs with activated human platelets was validated in vitro. MPFs were radiolabeled with $^{99m}$Tc [158] and used to image an aneurysmal thrombus in a rat model. Iron oxide embedded MPFs showed a high affinity for activated Human platelets in vitro and MR images of aneurysmal thrombus and activated endothelium were also obtained in murine models [159]. In another study, the authors developed MPFs containing
USPIO for magnetic resonance imaging [159]. On animal models a significant contrast enhancement of thrombus was obtained from 30 min to 2 h after the injection of MPFs.

In 2014, Li et al. developed a contrast agent for PET imaging [162]. FF was labelled with gallium 68 to image vulnerable active atherosclerosis plaques expressing P-selectin. After the validation with in vitro and ex vivo studies, they localized atherosclerotic plaques on an apolipoprotein E–deficient mice model using PET imaging. Anatomic structures of plaque were confirmed by 17.6 T MRI to correlate their results. The P-selectin affinity PET tracer was found to discriminate active and inactive atherosclerotic plaques.

4.3. Fucoidans in Regenerative Medicine

Marine polysaccharides have been used for years to design scaffolds for tissue engineering due to their interesting bioactivities and their biocompatibility. Senni et al. reviewed the studies in this field [192]. Particularly, fucoidans have raised interest in the design of biocomposites, especially for bone tissue engineering. So it is not surprising to find now the most advanced developments in this domain although there are still comparatively very few studies.

In 2008, Changotade et al. treated a commercial bone substitute (Lubboc®) with a low molecular weight FF (LMWF) to improve bone regeneration [185]. The authors found out that the pretreatment of the bone substitute with LMWF promotes human osteoblast proliferation, collagen type I expression and favors alkaline phosphatase activity enhancing the mineralization of the bone tissue. Regarding the origin and structure of LMWF used, the authors refer to older works without specifying any product parameter used in their study.

Three years later, Jin et al. developed polycaprolactone (PCL)/fucoidan composite scaffolds for bone tissue regeneration [186]. PCL/FF scaffolds with a 300 µm pore size dramatically increased the hydrophilic properties (with ≥5 wt % of fucoidans). In addition mechanical properties were improved even with a low fucoidan/PCL ratio (as an example: a 22% increase of Young’s modulus at 10 wt % of fucoidans). The biocompatibility of the scaffolds was assessed on osteoblast-like-cells (MG63) evidencing a better cell adhesion to the surface of the FF-containing scaffolds with three times more mineralization compared to the pure PCL scaffold after 14 days of cell culture. At the same time, Lee et al. prepared a biocomposite of polycaproactone (PCL) and FF [187]. The biocomposite showed a better distribution of osteoblast-like cells (MG63) compared to pure PCL mats. Furthermore, total protein content, alkaline phosphatase activity, and calcium mineralization were better and were higher with PCL/FF micro/nanofibrous mats suggesting that FF-complemented biocomposites would make good candidates for tissue engineering applications.

Since 2013, S. K. Kim’s group has been developing scaffolds from hydroxyapatite/poly saccharide-based nanocrystals for bone tissue regeneration [181–183]. Chitosan/alginate scaffold (CAS) and chitosan/alginate/fucoidan scaffold (CAFFS) were first prepared. CAFFS with a pore size of 56–437 nm improved cytocompatibility, proliferation, and alkaline phosphatase secretion of MG63 osteosarcoma cells as compared to CAS. In addition, protein adsorption and mineralization were two times greater with CAFFS, which was attributed to the negative charges of FF sulfate groups. Then, they prepared scaffolds from hydroxyapatite (HapS) and hydroxyapatite mixed with FF (HapFFS) to induce FGF-2 activity and angiogenesis [182]. HapFFS showed a mineralization effect two times higher than HapS. Scaffolds obtained more recently by mixing HapFFS with chitosan evidenced a better mineralization as well as a good biocompatibility with mesenchymal stem cells (PMSCs) likely due to a suitable micro architecture for cell growth and nutrient supplementation [183]. Note that no data about the FF were provided for the two first studies.

In 2015, Puvaneswary et al. prepared tricalcium phosphate-chitosan-fucoidan biocomposite scaffold and demonstrated the benefic effect of FF [184]. They showed that the addition of FF in the scaffold increased the release of osteocalcin allowing the osteogenic differentiation of human mesenchymal stromal cells in vitro. Furthermore, FF was found to improve the compression strength and the biomineralization of the scaffolds.
5. Discussion

Fucoidan-containing nanosystems were first developed for the delivery of different therapeutic agents [147] followed by studies on regenerative medicine and more recently on diagnostics. Most of them focused on structures obtained from a mixture of FF and chitosan, a cationic polysaccharide with a random alternation of β(1→4)-D-glucosamine, and N-acetyl-D-glucosamine. The formation of these nanosystems occurs from electrostatic interactions between sulfate and ammonium groups to generate multilayer architectures stable over a wide range of pH values and suitable for oral or parenteral administration. Different methods were used to obtain fucoidan-containing nanosystems such as emulsion, self-assembly, coacervation, polyelectrolyte complexing or ionic cross-linking, all without risks of modification of the polymer structure. Although, in some cases, fucoidans were used for their intrinsic biological properties, for most of these studies they appear to have been used more for an ability to form stable structures with chitosan, as well as for pre-supposed harmlessness. Interestingly, physicochemical data for chitosan are often more detailed than for FF for which they are in general limited and sometimes even absent. Indeed, as evidenced in Table 3, in most cases the origin of FF is the only information provided, and, as a consequence, it is difficult to compare the results. Only three studies provide sufficient characteristics to the readers, and additional works are needed for discussion [158,176,191]. On one hand, this lack of structural data does not allow drugs to be created based on these polysaccharides [193]. On the other hand, the developments for Human health improvements require well-defined reproducible fucoidan fractions. If not, the conclusions are unique for a particular fraction, and, as a consequence, the results cannot be reproduced.

Fucoidans are polysaccharides, one of the three families of natural macromolecules with proteins and nucleic acids. Scientists have been able to fully synthesize the latter two for several decades. However the complexity of fucoidan structures has significantly delayed this essential step in their development to Human health, and overall progress in this domain suffers from a lack of tools such as those that are readily available for studying nucleic acids and proteins. More generally, once a particular carbohydrate structure has been identified as being responsible for a biological effect, it often has to be synthesized in order to establish or confirm its structure assignment. Nevertheless, dedicated synthesis methods are time-consuming, limited to oligosaccharides, and practiced mostly by specialized laboratories using processes that may take months to years because of the structural complexity of these compounds. As a consequence, despite the prevalent role of polysaccharides and oligosaccharides in a wide range of biological processes, it is not surprising that there are so few carbohydrate based therapeutics and diagnostics on the market. In addition to monosaccharide-inspired drugs such as the influenza virus treatment Tamiflu (oseltamivir phosphate; Roche, Bâle, Switzerland), two drugs: acarbose (Precose, Glucobay; Bayer, Leverkusen, Germany) and heparin, stand out [194]. Note that both compounds were derived by isolation and reached the clinic before a detailed structure–activity relationship had been established. In particular, low molecular weight heparin (LMWH) (lovenox; Sanofi, Gentilly, France), mainly extracted from pig intestines and fractioned via chromatography, chemical cleavage or enzymatic hydrolysis, is still the only polysaccharide used in Human health since its first clinical trial reported in the early 80’s [195–198]. FF production follows the same process but the raw material is from vegetal origin, thereby preventing all contaminations attributed to animal products. However Health agencies have hardened the legislation about new pharmaceuticals in the last decade due to health scandals (in particular implicating LMWH in 2008 [199]), making FF more difficult to reach the market or even impossible without a reliable source. Anyway, scientists and companies who want to develop fucoidan-containing nanosystems up to clinical use must provide robust data about their product.

Nanomedicine approaches have revolutionized the treatment of human pathologies, in particular cancer and cardiovascular diseases [200,201]. Drugs are entrapped within sterically stabilized, long-circulating vehicles (therapeutics). Imaging markers such as radiolabels, USPIO or quantum dots allow real-time visualization of pathological areas (diagnostics). The theranostic strategy associates
both types in unique structures. These tailor-made nanosystems are built from polymers, carbon
nanosheets, lipids, metal oxides etc., sometimes mixed to get hybrid structures, shaped as spheres,
rods, capsules or more complicated geometry, and surface-modified to improve their efficacy and
decrease side-toxicity. Ultimately they can be grafted with ligands to target cellular/molecular
components of the diseases \[200,201\]. Bioactive carbohydrates, and in particular fucoidan fractions,
are good candidates thanks to their overall biocompatibility, high versatility with regard to
chemical modifications, and relatively low production costs. However the clinical development
of fucoidan-based biospecific systems for nanomedicine remains a challenge because it requires not
only a translational approach involving a partnership with pharmaceutical companies and respecting
specifications approved by Health agencies \[202\] but also implementing a secure process to obtain
reliable fractions.

In this context, we have considered a rational approach in order to develop a clinical contrast
agent using FF (see \[55,156,158,191\]). From the pioneer works of Varki et al. \[75\], P-selectin was
confirmed as a relevant molecular target of a commercial FF (Ascophyscient\textsuperscript{®} from Algues & Mer,
Ile d’Ouessant, France: a low molecular weight fucoidan fraction from Ascophyllum nodosum). In 2013,
a joint laboratory was created with the Algues & Mer Company to secure the production of reproducible
FF with well-defined composition and molecular weight. In 2015, these fucoidans were labeled by the
French authorities as “raw materials for pharmaceutical uses”. Today, they are part of the European
project Nanoathero for the development of a SPECT marker for human atherothrombosis \[203\] and
clinical trials will start soon.

6. Conclusions

Fucoidans are abundant polysaccharides with remarkable biological properties. Their vegetal
origins (considering that fucoidans extracted from marine animals are a tiny part of the total amount),
the absence of adverse effects, and an affordable price due to easy-to-handle production processes
make them promising for Human health. However these advantages are also the main bottlenecks
for developments in nanomedicine due to the difficulty in obtaining reproducible chemical structures
and molecular weights from one batch to another. Up to now, fucoidans in nanomedicine have been
mainly used for protein or drug delivery with few studies about medical imaging; applications to
regenerative medicine being still limited to bone tissue regeneration in animals. So far, isolation from
natural sources is the only effective way to get fucoidans, but it is no longer possible to consider the
molecular weight together with L-fucose and sulfate contents of a bioactive fraction as the only relevant
parameters for further developments. The use of fucoidans in nanomedicine will be legitimated only
by a translational strategy from a reproducible starting material with a defined and reproducible
structure. This goal can be achieved only via two ways: (i) validation of an industrial production from
natural extracts; or (ii) total synthesis with enzymes or chemical reactions. Currently, the first way
is available; the second one is likely within the next decades \[45\]. The biomedical market represents
an enormous opportunity for fucoidans, as their potential added value can, in principle, justify the
inherent risk related with the development and approval of such products. Moreover, the possibility
of developing a wide variety of chemically modified derivatives makes fucoidans versatile materials
that could be applied in other fields of technological interest. This is a continuing challenge to polymer
and biomaterial scientists, but it is already possible to anticipate that these strategic approaches will
widens up perspectives and potential applications in the future.

Acknowledgments: This work was supported by Inserm and University Paris 13 and the competitiveness cluster
Medicen Paris Region. P.S. is a recipient of the grant from University Paris 13 and IMOVA project founded by
FUI/OSEO. L.C. is a recipient of a CIFRE grant from ANRT (ANR-13-RPIB-0006 “FucoThrombo”). The authors
acknowledge the financial supports from FP7 NMP-LA-2012-309820 “NanoAthero”, ANR-13-LABI-0005-01
“FucoChem” and ANR-13-RPIB-0006 “FucoThrombo”.

Conflicts of Interest: The founding sponsors had no role in the design of the study; in the collection, analyses, or
interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
References

1. Michel, G.; Tonon, T.; Scornet, D.; Cock, J.M.; Kloareg, B. The cell wall polysaccharide metabolism of the brown alga *Ectocarpus siliculosus*. Insights into the evolution of extracellular matrix polysaccharides in Eukaryotes. *New Phytol.* 2010, 188, 82–97. [CrossRef] [PubMed]

2. Kloareg, B.; Quatrano, R.S. Structure of the cell walls of marine algae and ecophysiological functions of the matrix polysaccharides. *Oecologia, Mar. Biol.* 1988, 26, 259–315.

3. Kylin, H. Zur Biochemie der Meeresalgen. *Z. Physiol. Chem.* 1913, 83, 171–197. [CrossRef]

4. Berteau, O.; Mulloy, B. Sulfated fucans, fresh perspectives: Structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. *Glycobiology* 2003, 13, 29–40. [CrossRef] [PubMed]

5. Morya, V.K.; Kim, J.; Kim, E.K. Algal fucoidan: Structural and size-dependent bioactivities and their perspectives. *Appl. Microbiol. Biotechnol.* 2012, 93, 71–82. [CrossRef] [PubMed]

6. Li, B.; Lu, F.; Wei, X.; Zhao, R. Fucoidan: Structure and Bioactivity. *Molecules* 2008, 13, 1671–1695. [CrossRef] [PubMed]

7. Usov, A.I.; Bilan, M.I. Fucoids—Sulfated polysaccharides of brown algae. *Russ. Chem. Rev.* 2009, 78, 785–799. [CrossRef]

8. Bilan, M.I.; Usov, A.I. Structural Analysis of Fucoids. *Nat. Prod. Commun.* 2008, 3, 1639–1648.

9. Ale, M.T.; Meyer, A.S. Fucoidans from brown seaweeds: An update on structures, extraction techniques and use of enzymes as tools for structural elucidation. *RSC Adv.* 2013, 3, 8131–8141. [CrossRef]

10. Ustyuzhanina, N.E.; Bilan, M.I.; Ushakova, N.A.; Usov, A.I.; Kiselevsky, M.V.; Nifantiev, N.E. Fucoidans: Pro- or antiangiogenic agents? *Glycobiology* 2014, 24, 1265–1274. [CrossRef] [PubMed]

11. Pomin, V.H. Fucanomics and Galactanomics: Current Status in Drug Discovery, Mechanisms of Action and Role of the Well-defined Structures. *Biochem. Biophys. Acta.* 2012, 1820, 1971–1979. [CrossRef] [PubMed]

12. Ale, M.T.; Mikkelsen, J.D.; Meyer, A.S. Important Determinants for Fucoidan Bioactivity: A Critical Review of Structure-Function Relations and Extraction Methods for Fucose-Containing Sulfated Polysaccharides from Brown Seaweeds. *Mar. Drugs* 2011, 9, 2106–2130. [CrossRef] [PubMed]

13. Vasseur, E.; Setälä, K.; Gjertsen, P. Chemical Studies on the Jelly Coat of the Sea-Urchin Egg. *Acta Chem. Scand.* 1948, 2, 900–913. [CrossRef]

14. Pomin, V.H. Fucanomics and Galactanomics: Marine Distribution, Medicinal Impact, Conceptions, and Challenges. *Mar. Drugs* 2012, 10, 793–811. [CrossRef] [PubMed]

15. Deniaud-Bouë, É.; Kervarec, N.; Michel, G.; Tonon, T.; Kloareg, B.; Hervé, C. Chemical and enzymatic fractionation of cell walls from Fucales: Insights into the structure of the extracellular matrix of brown algae. *Ann. Bot.* 2014, 114, 1203–1216. [CrossRef] [PubMed]

16. Alves, A.P.; Mulloy, B.; Diniz, J.A.; Mourao, P.A.S. Sulfated polysaccharides from the egg jelly layer are species-specific inducers of acrosomal reaction in sperm of sea urchins. *J. Biol. Chem.* 1997, 272, 6965–6971. [CrossRef] [PubMed]

17. Vilela-Silva, A.-C.E.S.; Castro, M.O.; Valente, A.-P.; Biermann, C.H.; Mourão, P.A.S. Sulfated fucans from the egg jellies of the closely related sea urchins *Strongylocentrotus droebachiensis* and *Strongylocentrotus pallidus* ensure species-specific fertilization. *J. Biol. Chem.* 2002, 277, 379–387. [CrossRef] [PubMed]

18. Mourão, P.A.; Bastos, I.G. Highly acidic glycans from sea cucumbers. Isolation and fractionation of fucose-rich sulfated polysaccharides from the body wall of *Ludwigothurea grisea*. *Eur. J. Biochem.* 1987, 166, 639–645. [CrossRef] [PubMed]

19. Conchie, J.; Percival, E.G.V. Fucoidin. Part II. The hydrolysis of a methylated fucoidin prepared from *Fucus vesiculosus*. *J. Chem. Soc.* 1950, 827–832. [CrossRef]

20. Patankar, M.S.; Oehninger, S.; Barnett, T.; Williams, R.L.; Clark, G.F. A revised structure for fucoidan may explain some of its biological activities. *J. Biol. Chem.* 1993, 268, 21770–21776. [PubMed]

21. Nishino, T.; Nishioka, C.; Ura, H.; Nagumo, T. Isolation and partial characterization of a novel amino sugar-containing fucan sulfate from commercial *Fucus vesiculosus* fucoidan. *Carbohydr. Res.* 1994, 255, 213–224. [CrossRef]

22. Chevolot, L.; Mulloy, B.; Ratiskol, J.; Foucault, A.; Colliec-Jouault, S. A disaccharide repeat unit is the major structure in fucoids from two species of brown algae. *Carbohydr. Res.* 2001, 330, 529–535. [CrossRef]
23. Bilan, M.I.; Grachev, A.A.; Ustuzhanina, N.E.; Shashkov, A.S.; Nifantiev, N.E.; Usov, A.I. Further studies on the composition and structure of a fucoidan preparation from the brown seaweed *Fucus evanesens* C. Ag. *Carbohydr. Res.* 2002, 337, 719–730. [CrossRef]  
24. Bilan, M.I.; Grachev, A.A.; Shashkov, A.S.; Kelly, M.; Sanderson, C.J.; Nifantiev, N.E.; Usov, A.I. Structure of a fucoidan from the brown seaweed *Fucus evanesens* C. Ag. *Carbohydr. Res.* 2010, 345, 2038–2047. [CrossRef] [PubMed]  
25. Sinurat, E.; Peranginangin, R.; Saepudin, E. Purification and Characterization of Fucoidan from the Brown Seaweed *Sargassum binderi* Sonder. *Squalean Bull. Mar. Fish. Postharvest Biotechnol.* 2016, 10, 79–87. [CrossRef]  
26. Luo, D.; Yuan, X.; Zeng, Y.; Nie, K.; Li, Z.; Wang, Z. Structure elucidation of a major fucopyranose-rich heteropolysaccharide (STP-II) from *Sargassum thunbergii*. *Carbohydr. Polym.* 2016, 143, 1–8. [CrossRef] [PubMed]  
27. Usov, A.I.; Smirnova, G.P.; Bilan, M.I.; Shashkov, A.S. Polysaccharides of algae. 53. Brown alga *Laminaria saccharina* (L.) Lam. as a source of fucoidan. *Bioorg. Khim.* 1998, 24, 437–445.  
28. Chizhov, A.O.; Dell, A.; Morris, H.R.; Haslam, S.M.; McDowell, R.A.; Shashkov, A.S.; Nifantiev, N.E.; Khaltuntseva, E.A.; Usov, A.I. A study of fucoidan from the brown seaweed *Chorda filum*. *Carbohydr. Res.* 1999, 320, 108–119. [CrossRef]  
29. Mulloy, B.; Ribeiro, A.C.; Alves, A.P.; Vieira, R.P.; Mourao, P.A. Sulfated fucans from echinoderms have a regular tetrasaccharide repeating unit defined by specific patterns of sulfation at the 0–2 and 0–4 positions. *J. Biol. Chem.* 1999, 269, 22113–22123. [PubMed]  
30. Vilela-Silva, A.-C.E.S.; Alves, A.-P.; Valente, A.-P.; Vacqueri, V.D.; Mourao, P.A.S. Structure of the sulfated alpha-L-fucan from the egg jelly coat of the sea urchin *Strongylocentrotus franciscanus*: Patterns of preferential 2-O- and 4-O-sulfation determine sperm cell recognition. *Glycobiology* 1999, 9, 927–933. [CrossRef] [PubMed]  
31. Chevolot, L.; Foucault, A.; Chaubet, F.; Kervarec, N.; Sinquin, C.; Fisher, A.-M.; Boisson-Vidal, C. Further data on the structure of brown seaweed fucans: Relationships with anticoagulant activity. *Carbohydr. Res.* 1999, 319, 154–165. [CrossRef]  
32. Yuan, Y.; Macquarrie, D.J. Microwave assisted step-by-step process for the production of fucoidan, alginate sodium, sugars and biochar from *Ascophyllum nodosum* through a biorefinery concept. *Bioresour. Technol.* 2015, 198, 819–827. [CrossRef] [PubMed]  
33. Larsen, B.; Haug, A.; Painter, T.J. Sulphated Polysaccharides in Brown Algae. I. Isolation and Preliminary Characterisation of Three Sulphated Polysaccharides from *Ascophyllum nodosum*. *Acta Chem. Scand.* 1966, 20, 219–230. [CrossRef]  
34. Nardella, A.; Chaubet, F.; Boisson-Vidal, C.; Blondin, C.; Durand, P.; Jozefonvicz, J. Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed *Ascophyllum nodosum*. *Carbohydr. Res.* 1996, 289, 201–208. [CrossRef]  
35. Kusaykin, M.; Bakunina, I.; Sova, V.; Ermakova, S.; Kuznetsova, T.; Besednova, N.; Zaporozhets, T.; Zvyagintseva, T. Structure, biological activity, and enzymatic transformation of fucoids from the brown seaweed *Ascophyllum nodosum*. *Biotechnol. J.* 2008, 3, 904–915. [CrossRef] [PubMed]  
36. Kim, W.J.; Park, J.W.; Park, J.K.; Choi, D.J.; Park, Y.I. Purification and Characterization of a Fucoidanase (FNase S) from a Marine Bacterium *Sphingomonas paucimobilis* PF-1. *Mar. Drugs* 2015, 13, 4398–4417. [CrossRef] [PubMed]  
37. Silchenko, A.S.; Kusaykin, M.I.; Kurilenko, V.V.; Zakharenko, A.M.; Isakov, V.V.; Zaporozhets, T.S.; Gazha, A.K.; Zvyagintseva, T.N. Hydrolysis of Fucoidan by Fucoidanase Isolated from the Marine Bacterium, *Formosa algae*. *Mar. Drugs* 2013, 11, 2413–2430. [CrossRef] [PubMed]  
38. Martin, M.; Barbayron, T.; Martin, R.; Portetelle, D.; Michel, G.; Vandenbol, M. The Cultivable Surface Microbiota of the Brown Alga *Ascophyllum nodosum* is Enriched in Macroalgal-Polysaccharide-Degrading Bacteria. *Front. Microbiol.* 2015, 6, 1487. [CrossRef] [PubMed]  
39. Silchenko, A.S.; Khanh, H.H.N.; Hang, C.T.T.; Kurilenko, V.V.; Zakharenko, A.M.; Zueva, A.O.; Ly, B.M.; Kusaykin, M.I. A Simple Plate Method for the Screening and Detection of Fucoidanases. *Achiev. Life Sci.* 2015, 9, 94–106. [CrossRef]  
40. Kim, H.-J.; Choi, J.-I.; Park, J.-G.; Song, B.-S.; Kim, J.-H.; Yoon, Y.; Kim, C.-J.; Shin, M.-H.; Byun, M.-W.; Lee, J.-W. Effects of Combined Treatment of Gamma Irradiation and Addition of Fucoidan/laminarin on Ready-to-eat Pork Patty. *Korean J. Food Sci. Anim. Resour.* 2009, 29, 34–39. [CrossRef]
41. Choi, J.; Kim, H.-J. Preparation of low molecular weight fucoidan by gamma-irradiation and its anticaner activity. *Carbohydr. Polym.* 2013, 97, 358–362. [CrossRef] [PubMed]
42. Choi, J.; Lee, S.G.; Han, S.J.; Cho, M.; Lee, PC. Effect of gamma irradiation on the structure of fucoidan. *Radiat. Phys. Chem.* 2014, 100, 54–58. [CrossRef]
43. Silchenko, A.S.; Kusaykin, M.I.; Zakharenko, A.M.; Menshova, R.V.; Khanh, H.H.N.; Dmitrenok, P.S.; Isakov, V.V.; Zvyagintseva, T.N. Endo-1,4-fucoidanase from Vietnamese marine mollusk *Lambis* sp. which producing sulphated fucooligosaccharides. *J. Mol. Catal. B Enzym.* 2014, 102, 154–160. [CrossRef]
44. Gerbst, A.G.; Grachev, A.A.; Ustyuzhanina, N.E.; Khatuntseva, E.A.; Tsvetkov, D.E.; Usov, A.I.; Shashkov, A.S.; Preobrazhenskaya, M.E.; Ushakova, N.A.; Nifantiev, N.E. The Synthesis and NMR and Conformational Studies of Fucoidan Fragments: VI. Fragments with an α-(1→2)-Linked Fucooligosaccharide Unit. *Russ. J. Bioorg. Chem.* 2003, 30, 137–147. [CrossRef]
45. Krylov, V.B.; Kaskova, Z.M.; Vinitskii, D.Z.; Ustyuzhanina, N.E.; Grachev, A.A.; Chizhov, A.O.; Nifantiev, N.E. Acid-promoted synthesis of per-O-sulfated fucooligosaccharides related to fucoidan fragments. *Carbohydr. Res.* 2011, 346, 540–550. [CrossRef] [PubMed]
46. Hsu, C.H.; Hung, S.C.; Wu, C.Y.; Wong, C.H. Toward Automated Oligosaccharide Synthesis. *Angew. Chem. Int. Ed.* 2011, 50, 11872–11923. [CrossRef] [PubMed]
47. Delattre, C.; Michaud, P.; Courtois, B.; Courtois, J. Oligosaccharides engineering from plants and algae. Applications in biotechnology and therapeutic. *Minerva Biotechnol.* 2005, 17, 107–117.
48. Nugent, M.A. Heparin sequencing brings structure to the function of complex oligosaccharides. *Proc. Natl. Acad. Sci. USA* 2000, 97, 10301–10303. [CrossRef] [PubMed]
49. Lauder, R.M.; Huckerby, T.N.; Nieduszynski, I.A. A fingerprinting method for chondroitin/dermatan sulfate and hyaluronan oligosaccharides. *Glycobiology* 2000, 10, 393–401. [CrossRef] [PubMed]
50. Hricovini, M.; Guerrini, M.; Bisio, A. Structure of heparin-derived tetrasaccharide complexed to the plasma protein antithrombin derived from NOEs, J-couplings and chemical shifts. *Eur. J. Biochem.* 1999, 261, 789–801. [CrossRef] [PubMed]
51. Pineo, G.F.; Hull, R.D. Low-molecular-weight heparin: Prophylaxis and treatment of venous thromboembolism. *Annu. Rev. Med.* 1997, 48, 79–91. [CrossRef] [PubMed]
52. Liu, J.; Shriver, Z.; Pope, R.M.; Thorp, S.C.; Copeland, R.J.; Raska, C.S.; Yoshida, K.; Eisenberg, R.J.; Cohen, G.; et al. Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. *J. Biol. Chem.* 2002, 277, 33456–33467. [CrossRef] [PubMed]
53. Ghatak, S.; Misra, S.; Toole, B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. *J. Biol. Chem.* 2002, 277, 38013–38020. [CrossRef] [PubMed]
54. Cumashi, A.; Ushakova, N.A.; Preobrazhenskaya, M.E.; D’Incecco, A.; Piccoli, A.; Totani, L.; Tinari, N.; Morozевич, G.E.; Berman, A.E.; Bilan, M.I.; et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. *Glycobiology* 2007, 17, 541–552. [CrossRef] [PubMed]
55. Bachelet, L.; Berthon, I.; Lavigne, D.; Vassy, R.; Jandrot-Perrus, M.; Chaubet, F.; Letourneur, D. Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. *Biochim. Biophys. Acta* 2009, 1790, 141–146. [CrossRef] [PubMed]
56. Blondin, C.; Fischer, E.; Boisson-Vidal, C.; Kazatchkine, M.D.; Jozefonvicz, J. Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweeds. *Mol. Immunol.* 1994, 31, 247–253. [CrossRef]
57. Springer, G.F.; Wurzel, H.A.; Mcneal, G.M.; Ansell, N.J.; Doughty, M.F. Isolation of anticoagulant fractions from crude fucoidin. *Proc. Soc. Exp. Biol. Med. Soc. Exp. Biol.* 1957, 94, 404–409. [CrossRef]
58. Zhao, X.; Guo, F.; Hu, J.; Zhang, L.; Xue, C.; Zhang, Z.; Li, B. Antithrombotic activity of oral administered low molecular weight fucoidan from *Laminaria japonica*. *Thromb. Res.* 2016, 144, 46–52. [CrossRef] [PubMed]
59. Zaporozhets, T.; Besednova, N. Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardio-vascular system: *Review. Pharm. Biol.* 2016, 1–10. [CrossRef] [PubMed]
60. Tissot, B.; Daniel, R. Biological properties of sulfated fucans: The potent inhibiting activity of algal fucoidan against the human complement system. *Glycobiology* 2003, 13, 29–30. [CrossRef] [PubMed]
61. Wang, W.; Wang, S.-X.; Guan, H.-S. The Antiviral Activities and Mechanisms of Marine Polysaccharides: An Overview. *Mar. Drugs* 2012, 10, 2795–2816. [CrossRef] [PubMed]
62. Schaeffer, D.J.; Krylov, V.S. Anti-HIV Activity of Extracts and Compounds from Algae and Cyanobacteria. *Ecotoxicol. Environ. Saf.* 2000, 45, 208–227. [CrossRef] [PubMed]

63. Vo, T.S.; Kim, S.-K. Potential Anti-HIV Agents from Marine Resources: An Overview. *Mar. Drugs* 2010, 8, 2871–2892. [CrossRef] [PubMed]

64. Harrop, H.A.; Rider, C.C.; Coombe, D.R. Sulphated polysaccharides exert anti-HIV activity at differing sites. *Biochem. Soc. Trans.* 1992, 20, 1635. [CrossRef] [PubMed]

65. Dinesh, S.; Menon, T.; Hanna, L.E.; Suresh, V.; Sathuvan, M.; Manikannan, M. In vitro anti-HIV-1 activity of fucoidan from *Sargassum swartzi*. *Int. J. Biol. Macromol.* 2016, 82, 83–88. [CrossRef] [PubMed]

66. Baba, M.; Snoeck, R.; Pauwels, R.; De Clercq, E. Sulfated polysaccharides are potent and selective inhibitors of human immunodeficiency virus. *Antimicrob. Agents Chemother.* 1998, 32, 1742–1745. [CrossRef] [PubMed]

67. McClure, M.O.; Moore, J.P.; Blanc, D.E.; Scotting, P.; Cook, G.M.W.; Keynes, R.J.; Weber, J.N.; Davies, D.; Weiss, R.A. Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. *AIDS Res. Hum. Retrovir.* 1992, 8, 19–26. [CrossRef] [PubMed]

68. Ponce, N.M.A.; Pujol, C.A.; Damonte, E.B.; Flores, M.L.; Stortz, C.A. Fucoidans from the brown seaweed *Adenoscytis utricularis*: Extraction methods, antiviral activity and structural studies. *Carbohydr. Res.* 2003, 338, 153–165. [CrossRef]

69. Kubes, P.; Jutila, M.; Payne, D. Therapeutic potential of inhibiting leukocyte rolling in ischemia/reperfusion. *J. Clin. Invest.* 1995, 95, 2510–2519. [CrossRef] [PubMed]

70. Omata, M.; Matsui, N.; Inomata, N.; Ohno, T. Protective effects of polysaccharide fucoidin on myocardial ischemia-reperfusion injury in rats. *J. Cardiovasc. Pharmacol.* 1997, 30, 717–724. [CrossRef] [PubMed]

71. Granert, C.; Raud, J.; Waage, A.; Lindquist, L. Effects of polysaccharide fucoidin on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit. *Infect. Immun.* 1999, 67, 2071–2074. [PubMed]

72. Wu, G.J.; Shiu, S.M.; Hsieh, M.C.; Tsai, G.J. Anti-inflammatory activity of a sulfated polysaccharide from the brown alga *Adenoscytis utricularis*. *Phytomedicine* 2016, 53, 16–23. [CrossRef]

73. Lasky, L.A. Selectin-carbohydrate interactions and the initiation of the inflammatory response. *Annu. Rev. Biochem.* 1995, 64, 113–139. [CrossRef] [PubMed]

74. Wen, Z.S.; Xiang, X.W.; Jin, H.X.; Guo, X.Y.; Liu, L.J.; Huang, Y.N.; OuYang, X.K.; Qu, Y.L. Composition and anti-inflammatory effect of polysaccharides from *Sargassum horneri* in RAW264.7 macrophages. *Int. J. Biol. Macromol.* 2016, 88, 403–416. [CrossRef] [PubMed]

75. Variki, A. Selectin ligands. *Proc. Natl. Acad. Sci. USA* 1994, 91, 7390–7397. [CrossRef]

76. Myers, S.P.; O’Connor, J.; Fitzon, J.H.; Brooks, L.; Rolfe, M.; Connellan, P.; Wohlmuth, H.; Cheras, P.A.; Morris, C.A. A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. *Biol. Targets Ther.* 2010, 4, 33–44. [CrossRef]

77. Liu, F.; Wang, J.; Chang, A.K.; Liu, B.; Yang, L.; Li, Q.; Wang, P.; Zou, X. Fucoidan extract derived from *Undaria pinnatifida* inhibits angiogenesis by human umbilical vein endothelial cells. *Phytomedicine* 2012, 19, 797–803. [CrossRef] [PubMed]

78. Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. *Biochem. Pharmacol.* 2003, 65, 173–179. [CrossRef]

79. Soeda, S.; Kozako, T.; Iwata, K.; Shimeno, H. Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: Its possible mechanism of action. *Biochim. Biophys. Acta Mol. Cell Res.* 2000, 1497, 127–134. [CrossRef]

80. Luyt, C.-E.; Meddahi-Pellé, A.; Ho-Tin-Noe, B.; Colliec-Jouault, S.; Guezennec, J.; Louedec, L.; Prats, H.; Jacob, M.-P.; Osborne-Pellegrin, M.; Letourneur, D.; et al. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. *J. Pharmacol. Exp. Ther.* 2003, 305, 24–30. [CrossRef] [PubMed]

81. Purnama, A.; Aid-Launais, R.; Haddad, O.; Maire, M.; Mantovani, D.; Letourneur, D.; Hlawaty, H.; Le Visage, C. Fucoidan in a 3D scaffold interacts with vascular endothelial growth factor and promotes neovascularization in mice. *Drug Deliv. Transl. Res.* 2015, 5, 187–197. [CrossRef] [PubMed]
82. Bouvard, C.; Galy-Fauroux, I.; Grelac, F.; Carpentier, W.; Lokajczyk, A.; Gandrille, S.; Colliec-Jouault, S.; Fischer, A.M.; Helley, D. Low-Molecular-Weight Fucoidan Induces Endothelial Cell Migration via the PI3K/AKT Pathway and Modulates the Transcription of Genes Involved in Angiogenesis. *Mar. Drugs* 2015, 13, 7446–7462. [CrossRef] [PubMed]

83. Haddad, O.; Guyot, E.; Marinval, N.; Chevalier, F.; Maillard, L.; Gadi, L.; Laguillier-Morizot, C.; Oudar, O.; Sutton, A.; Charnaux, N.; et al. Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis. *Mar. Drugs* 2015, 13, 6588–6608. [CrossRef] [PubMed]

84. Chabut, D.; Fischer, A.M.; Colliec-Jouault, S.; Laurendeau, I.; Matou, S.; Le Bonniec, B.; Helley, D. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha 6 overexpression. *Mol. Pharmacol.* 2003, 64, 696–702. [CrossRef] [PubMed]

85. Matou, S.; Helley, D.; Chabut, D.; Bros, A.; Fischer, A.M. Effect of fucoidan on fibroblast growth factor-2-induced angiogenesis in vitro. *Thromb. Res.* 2002, 106, 213–221. [CrossRef]

86. Giraux, J.-L.; Matou, S.; Bros, A.; Tapon-Bretaudiere, J.; Letourneur, D.; Fischer, A.-M. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. *Eur. J. Cell Biol.* 1998, 77, 352–359. [CrossRef]

87. Boisson-Vidal, C.; Zemani, F.; Caligiuri, G.; Galy-Fauroux, I.; Colliec-Jouault, S.; Helley, D.; Fischer, A.-M. Neoangiogenesis induced by progenitor endothelial cells: Effect of fucoidan from marine algae. *Cardiovasc. Hematol. Agents Med. Chem.* 2007, 5, 67–77. [CrossRef] [PubMed]

88. Kwak, J.-Y. Fucoidan as a marine anticancer agent in preclinical development. *Mar. Drugs* 2014, 12, 851–870. [CrossRef] [PubMed]

89. Han, Y.S.; Lee, J.H.; Lee, S.H. Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling. *Biomol. Ther.* 2015, 23, 225–232. [CrossRef] [PubMed]

90. Atashrazm, F.; Lowenthal, R.M.; Woods, G.M.; Holloway, A.F.; Dickinson, J.L. Fucoidan and cancer: A multifunctional molecule with anti-tumor potential. *Mar. Drugs* 2015, 13, 2327–2346. [CrossRef] [PubMed]

91. Jin, J.-O.; Song, M.-G.; Kim, Y.-N.; Park, J.-I.; Kwak, J.-Y. The mechanism of fucoidan-induced apoptosis in leukemic cells: Involvement of ERK1/2, JNK, glutathione, and nitric oxide. *Mol. Carcinog.* 2010, 49, 771–782. [CrossRef] [PubMed]

92. Park, H.S.; Hwang, H.J.; Kim, G.-Y.; Cha, H.-J.; Kim, W.-J.; Kim, N.D.; Yoo, Y.H.; Choi, Y.H. Induction of apoptosis by fucoidan in human leukemia U937 cells through activation of p38 MAPK and modulation of Bcl-2 family. *Mar. Drugs* 2013, 11, 2347–2364. [CrossRef] [PubMed]

93. Zhang, Z.; Teruya, K.; Yoshida, T.; Eto, H.; Shirahata, S. Fucoidan Extract Enhances the Anti-Cancer Activity of Chemotherapeutic Agents in MDA-MB-231 and MCF-7 Breast Cancer Cells. *Mar. Drugs* 2013, 11, 81–98. [CrossRef] [PubMed]

94. Park, H.S.; Kim, G.-Y.; Nam, T.-J.; Kim, N.D.; Choi, Y.H. Antiproliferative activity of fucoidan was associated with the induction of apoptosis and autophagy in AGS human gastric cancer cells. *J. Food Sci.* 2011, 76, 77–83. [CrossRef] [PubMed]

95. Boo, H.-J.; Hyun, J.-H.; Kim, S.-C.; Kang, J.-I.; Kim, M.-K.; Kim, S.-Y.; Cho, H.; Yoo, E.-S.; Kang, H.-K. Fucoidan from *Undaria pinnatifida* induces apoptosis in A549 human lung carcinoma cells. *Phytother. Res.* 2011, 25, 1082–1086. [CrossRef] [PubMed]

96. Boo, H.-J.; Hong, J.-Y.; Kim, S.-C.; Kang, J.-I.; Kim, M.-K.; Kim, E.-J.; Hyun, J.-W.; Koh, Y.-S.; Yoo, E.-S.; Kwon, J.-M.; et al. The anticancer effect of fucoidan in PC-3 prostate cancer cells. *Mar. Drugs* 2013, 11, 2982–2999. [CrossRef] [PubMed]

97. Yang, L.; Wang, P.; Wang, H.; Li, Q.; Teng, H.; Liu, Z.; Yang, W.; Hou, L.; Zou, X. Fucoidan derived from *Undaria pinnatifida* induces apoptosis in human hepatocellular carcinoma SMMC-7721 cells via the ROS-mediated mitochondrial pathway. *Mar. Drugs* 2013, 11, 1961–1976. [CrossRef] [PubMed]

98. Shu, Z.; Shi, X.; Nie, D.; Guan, B. Low-Molecular-Weight Fucoidan Inhibits the Viability and Invasiveness and Triggers Apoptosis in IL-1beta-Treated Human Rheumatoid Arthritis Fibroblast Synoviocytes. *Inflammation* 2015, 38, 1777–1786. [CrossRef] [PubMed]

99. Chen, M.C.; Hsu, W.L.; Hwang, P.A.; Chou, T.C. Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia. *Mar. Drugs* 2015, 13, 4436–4451. [CrossRef] [PubMed]
100. Wei, C.; Xiao, Q.; Kuang, X.; Zhang, T.; Yang, Z.; Wang, L. Fucoidan inhibits proliferation of the SKM-1 acute myeloid leukaemia cell line via the activation of apoptotic pathways and production of reactive oxygen species. Mol. Med. Rep. 2015, 12, 6649–6655. [CrossRef] [PubMed]

101. Abu, R.; Jiang, Z.; Ueno, M.; Isaka, S.; Nakazono, S.; Okimura, T.; Cho, K.; Yamaguchi, K.; Kim, D.; Oda, T. Anti-metastatic effects of the sulfated polysaccharide ascophyllan isolated from Ascophyllum nodosum on B16 melanoma. Biochem. Biophys. Res. Commun. 2015, 458, 727–732. [CrossRef] [PubMed]

102. Cho, Y.; Yoon, J.H.; Yoo, J.J.; Lee, M.; Lee, D.H.; Cho, E.J.; Lee, J.H.; Yu, S.J.; Kim, Y.J.; Kim, C.Y. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm. Sin. B 2015, 5, 544–553. [CrossRef] [PubMed]

103. Li, J.; Chen, K.; Li, S.; Feng, J.; Liu, T.; Wang, F.; Zhang, R.; Xu, S.; Zhou, Y.; Zhou, S.; et al. Protective effect of fucoidan from *Cucumaria frondosa* on liver fibrosis via the TGF-beta1/Smad pathway-mediated inhibition of extracellular matrix and autophagy. Drug Des. Dev. Ther. 2016, 10, 619–630.

104. Ikeguchi, M.; Saito, H.; Miki, Y.; Kimura, T. Effect of Fucoidan Dietary Supplement on the Chemotherapy Treatment of Patients with Unresectable Advanced Gastric Cancer. J. Cancer Ther. 2015, 6, 1020–1026. [CrossRef]

105. Zhang, S.M.; Xie, Z.P.; Xu, M.L.; Shi, L.F. Cardioprotective effects of fucoidan against hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Pharm. Biol. 2015, 53, 1352–1357. [CrossRef] [PubMed]

106. Shimizu, J.; Wada-Funada, U.; Mano, H.; Matahira, Y.; Kawaguchi, M.; Wada, M. Proportion of murine cytotoxic T cells is increased by high molecular weight fucoidan extracted from *Okinawa mozuku* (Cladosiphon okamuranus). J. Health Sci. 2005, 51, 394–397. [CrossRef]

107. Yang, C.; Chung, D.; Shina, I.-S.; Lee, H.; Kim, J.; Lee, Y.; You, S. Effects of molecular weight and hydrolysis conditions on anticancer activity of fucoidans from sporophyll of *Undaria pinnatifida*. Int. J. Biol. Macromol. 2008, 43, 433–437. [CrossRef] [PubMed]

108. Azuma, K.; Ishihara, T.; Nakamoto, H.; Amaha, T.; Osaki, T.; Tsuka, T.; Imagawa, T.; Minami, S.; Takashima, O.; Ifuku, S.; et al. Effects of oral administration of fucoidan extracted from *Cladosiphon okamuranus* on tumor growth and survival time in a tumor-bearing mouse model. Mar. Drugs 2012, 10, 2337–2348. [CrossRef] [PubMed]

109. Cho, M.L.; Lee, B.Y.; You, S.G. Relationship between oversulfation and conformation of low and high molecular weight fucoidans and evaluation of their in vitro anticancer activity. Molecules 2010, 16, 291–297. [CrossRef] [PubMed]

110. Akihiro, K.; Shinsuke, A.; Nozomi, K.; Daisuke, T.; Kazunobu, T. Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells. Org. Biomol. Chem. 2015, 13, 10556–10568.

111. Liu, B.; Kongstad, K.T.; Wiese, S.; Jäger, A.K.; Staerk, D. Edible seaweed as future functional food: profiling and HPLC–HRMS–SPE–NMR. Food Chem. 2016, 203, 16–22. [CrossRef] [PubMed]

112. Lakshmana, S.S.; Vinoth, K.T.; Geetharamani, D.; Suja, G.; Yesudas, R.; Chacko, A. Fucoidan—An alpha-amylase inhibitor from *Sargassum wightii* with relevance to NIDDM. Int. J. Biol. Macromol. 2015, 81, 644–647. [CrossRef] [PubMed]

113. Kim, K.T.; Rioux, L.E.; Turgeon, S.L. Molecular weight and sulfate content modulate the inhibition of alpha-amylase by fucoidan relevant for type 2 diabetes management. PharmaNutrition 2015, 3, 108–114. [CrossRef]

114. Chen, J.; Cui, W.; Zhang, Q.; Jia, Y.; Sun, Y.; Weng, L.; Luo, D.; Zhou, H.; Yang, L. Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes. Am. J. Transl. Res. 2015, 7, 1553–1563. [PubMed]

115. Heeba, G.H.; Morsy, M.A. Fucoidan ameliorates steatohepatitis and insulin resistance by suppressing oxidative stress and inflammatory cytokines in experimental non-alcoholic fatty liver disease. Environ. Toxicol. Pharmacol. 2015, 40, 907–914. [CrossRef] [PubMed]

116. Shan, X.; Liu, X.; Hao, J.; Cai, C.; Fan, F.; Dun, Y.; Zhao, X.; Li, C.; Yu, G. In vitro and in vivo hypoglycemic effects of brown algal fucoidans. Int. J. Biol. Macromol. 2015. [CrossRef] [PubMed]

117. Wang, Y.; Wang, J.; Zhao, Y.; Hu, S.; Shi, D.; Xue, C. Fucoidan from sea cucumber *Cucumaria frondosa* exhibits anti-hyperglycemic effects in insulin resistant mice via activating the PI3K/PKB pathway and GLUT4. J. Biosci. Bioeng. 2016, 121, 36–42. [CrossRef] [PubMed]
118. Wang, J.; Hu, S.; Jiang, W.; Song, W.; Cai, L. Fucoidan from sea cucumber may improve hepatic inflammatory response and insulin resistance in mice. *Int. Immunopharm.* 2015, 31, 15–23. [CrossRef] [PubMed]

119. Thelen, T.; Hao, Y.; Medeiros, A.I.; Curtis, J.L.; Serezani, C.H.; Kobzik, L.; Harris, L.H.; Aronoff, D.M. The class A scavenger receptor, macrophage receptor with collagenous structure, is the major phagocytic receptor for *Clostridium sordellii* expressed by human decidual macrophages. *J. Immunol.* 2010, 185, 4328–4335. [CrossRef] [PubMed]

120. Hu, Y.; Cheng, S.C.-S.; Chan, K.-T.; Ke, Y.; Xue, B.; Sin, F.W.-Y.; Zeng, C.; Xie, Y. Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells. *Biochem. Biophys. Res. Commun.* 2010, 392, 329–334. [CrossRef] [PubMed]

121. Yang, M.; Ma, C.; Sun, J.; Shao, Q.; Gao, W.; Zhang, Y.; Li, Z.; Xie, Q.; Dong, Z.; Qu, X. Fucoidan stimulation induces a functional maturation of human monocyte-derived dendritic cells. *Int. Immunopharm.* 2008, 8, 1754–1760. [CrossRef] [PubMed]

122. Hou, Y.; Wang, J.; Jin, W.; Zhang, H.; Zhang, Q. Degradation of *Laminaria japonica* fucoidan by hydrogen peroxide and antioxidant activities of the degradation products of different molecular weights. *Carbohydr. Polym.* 2012, 87, 153–159. [CrossRef] [PubMed]

123. Costa, L.S.; Fidelis, G.P.; Telles, C.B.S.; Dantas-Santos, N.; Camara, R.B.G.; Cordeiro, S.L.; Costa, M.S.S.P.; De Souza, M.C.R.; Marques, C.T.; Dore, C.M.G.; Da Silva, F.R.F.; Rocha, H.A.O.; Cheras, P.A.; Almeida-Lima, J.; Melo-Silveira, R.F.; Corre, V. Influence of Dietary Fucoidan Supplementation on Growth and Immunological Response of Juvenile *Marsupenaeus japonicus*. *J. World Aquac. Soc.* 2010, 41, 235–244. [CrossRef]

124. Holdt, S.L.; Kraan, S. Bioactive compounds in seaweed: Functional food applications and legislation. *J. Agric. Food Chem.* 2011, 59, 543–597. [CrossRef]

125. Rupérez, P.; Ahrazem, O.; Leal, J.A. Potential Antioxidant Capacity of Sulfated Polysaccharides from the Edible Marine Brown Seaweed *Fucus vesiculosus*. *J. Agric. Food Chem.* 2002, 50, 840–845. [CrossRef] [PubMed]

126. Myers, S.P.; O’Connor, J.; Fitton, J.H.; Brooks, L.; Rollfe, M.; Connellan, P.; Wohlmuth, H.; Cheras, P.A.; Morris, C. A combined Phase I and II open-label study on the immunomodulatory effects of seaweed extract nutrient complex. *Biol. Targets Ther.* 2011, 5, 45–60. [CrossRef] [PubMed]

127. De Souza, M.C.R.; Marques, C.T.; Dore, C.M.G.; Da Silva, F.R.F.; Rocha, H.A.O.; Leite, E.L. Antioxidant activities of sulfated polysaccharides from brown and red seaweeds. *J. Appl. Phycol.* 2007, 19, 153–160. [CrossRef] [PubMed]

128. Costa, L.S.; Fidelis, G.P.; Telles, C.B.S.; Dantas-Santos, N.; Camara, R.B.G.; Cordeiro, S.L.; Costa, M.S.S.P.; Almeida-Lima, J.; Melo-Silveira, R.F.; Oliveira, R.M.; et al. Antioxidant and antiproliferative activities of heterofucans from the seaweed *Sargassum filipendula*. *Mar. Drugs* 2011, 9, 952–966. [CrossRef] [PubMed]

129. Wang, J.; Zhang, Q.; Zhang, Z.; Li, Z. Antioxidant activity of fucoidan from sea cucumber may improve hepatic inflammatory response and insulin resistance in mice. *Int. Immunopharm.* 2015, 31, 15–23. [CrossRef] [PubMed]

130. Mak, W.; Hamid, N.; Liu, T.; Lu, J.; White, W.L. Fucoidan from New Zealand *Undaria pinnatifida*: Monthly variations and determination of antioxidant activities. *Carbohydr. Polym.* 2013, 92, 1991–1996. [CrossRef] [PubMed]

131. Liu, B.; Liu, S.; Xing, R.; Li, K.; Li, R.; Qin, Y.; Wang, X.; Wei, Z.; Li, P. Degradation of sulfated polysaccharides from *Enteromorpha prolifera* and their antioxidant activities. *Carbohydr. Polym.* 2013, 92, 606–614. [CrossRef] [PubMed]

132. Almeida-Lima, J.; Melo-Silveira, R.F.; Oliveira, R.M.; et al. Antioxidant and antiproliferative activities of sulfated polysaccharides from brown and red seaweeds. *J. Appl. Phycol.* 2007, 19, 153–160. [CrossRef] [PubMed]

133. O’Doherty, J.V.; McDonnell, P.; Figat, S. The effect of dietary laminarin and fucoidan in the diet of the weaning piglet on performance and selected faecal microbial populations. *Livest. Sci.* 2010, 134, 208–210. [CrossRef] [PubMed]

134. Traifalgar, R.F.; Kira, H.; Tung, H.T.; Michael, F.R.; Laining, A.; Yokoyama, S.; Ishikawa, M.; Koshio, S.; Serrano, A.E.; Corre, V. Influence of Dietary Fucoidan Supplementation on Growth and Immunological Response of Juvenile *Marsupenaeus japonicus*. *J. World Aquac. Soc.* 2010, 41, 235–244. [CrossRef] [PubMed]

135. Lynch, M.B.; Sweeney, T.; Callan, J.J.; O’Sullivan, J.T.; O’Doherty, J.V. The effect of dietary Laminaria derived laminarin and fucoidan on intestinal microflora and volatile fatty acid concentration in pigs. *Livest. Sci.* 2010, 133, 157–160. [CrossRef]
137. Walsh, A.M.; Sweeney, T.; O'Shea, C.J.; Doyle, D.N.; O'Doherty, J.V. Effect of supplementing varying inclusion levels of laminarin and fucoidan on growth performance, digestibility of diet components, selected faecal microbial populations and volatile fatty acid concentrations in weaned pigs. *Anim. Feed Sci. Technol.* 2013, 183, 151–159. [CrossRef]

138. Zaporozhets, T.S.; Besednova, N.N.; Kuznetsova, T.A.; Zvyagintseva, T.N.; Makarenkova, I.D.; Kryzhanovsky, S.P.; Melnikov, V.G. The prebiotic potential of polysaccharides and extracts of seaweeds. *Russ. J. Mar. Biol.* 2014, 40, 1–9. [CrossRef]

139. Moroney, N.C.; O'Grady, M.N.; O'Doherty, J.V.; Kerry, J.P. Addition of seaweed (*Laminaria digitata*) extracts containing laminarin and fucoidan to porcine diets: Influence on the quality and shelf-life of fresh pork. *Meat Sci.* 2012, 92, 423–429. [CrossRef] [PubMed]

140. Moroney, N.C.; O'Grady, M.N.; Lordan, S.; Stanton, C.; Kerry, J.P. Seaweed polysaccharides (laminarin and fucoidan) as functional ingredients in pork meat: An evaluation of anti-oxidative potential, thermal stability and bioaccessibility. *Mar. Drugs* 2015, 13, 2447–2464. [CrossRef] [PubMed]

141. Fitton, H.; Irhimeh, M.; Falk, N. Macroalgal fucoidan extracts: A new opportunity for marine cosmetics. *Cosmet. Toil.* 2007, 122, 55–64.

142. Hafner, A.; Lovric, J.; Lakos, G.P.; Pepic, I. Nanotherapeutics in the EU: An overview on current state and future directions. *Int. J. Nanomed.* 2014, 9, 1005–1023.

143. Mura, S.; Couvreur, P. Nanotheranostics for personalized medicine. *Adv. Drug Deliv. Rev.* 2012, 64, 1394–1416. [CrossRef] [PubMed]

144. Bates, S. Progress towards personalized medicine. *Drug Discov. Today* 2010, 15, 115–120. [CrossRef] [PubMed]

145. Sadee, W.; Dai, Z. Pharmacogenetics/genomics and personalized medicine. *Hum. Mol. Gen.* 2005, 2, 207–214. [CrossRef] [PubMed]

146. Venkatesan, J.; Anil, S.; Kim, S.-K.; Shim, M. Seaweed Polysaccharide-Based Nanoparticles: Preparation and Applications for Drug Delivery. *Polymers* 2016, 8, 30. [CrossRef]

147. Cunha, L.; Grenha, A. Sulfated Seaweed Polysaccharides as Multifunctional Materials in Drug Delivery Applications. *Mar. Drugs* 2016, 14, 42. [CrossRef] [PubMed]

148. Silva, V.A.J.; Andrade, P.L.; Silva, M.P.C.; Bustamante, A.D.; De Los Santos Valladares, L.; Albino Aguiar, J. Synthesis and characterization of Fe3O4 nanoparticles coated with fucan polysaccharides. *J. Magn. Magn. Mater.* 2013, 343, 138–143. [CrossRef]

149. Andrade, P.L.; Silva, V.A.J.; Silva, M.P.C.; Albino Aguiar, J. Synthesis and Characterization of Fucan-Coated Cobalt Ferrite Nanoparticles. *J. Supercond. Novel Magn.* 2012, 26, 2511–2514. [CrossRef]

150. Leung, T.C.-Y.W. C.K.; Xie, Y. Green synthesis of silver nanoparticles using biopolymers, carboxymethylated-curdlan and fucoidan. *Mater. Chem. Phys.* 2010, 121, 402–405. [CrossRef]

151. Nagarajan, S.; Kuppusamy, K.A. Extracellular synthesis of zinc oxide nanoparticle using seaweeds of gulf of Mannar, India. *J. Nanobiotechnol.* 2013, 11, 39. [CrossRef] [PubMed]

152. Soisuwans, S.; Warisnoicharoen, W.; Lirdprapamongkol, K.; Svasti, J. Eco-friendly synthesis of fucoidan-stabilized gold nanoparticles. *Am. J. Appl. Sci.* 2010, 7, 1038–1042.

153. Lee, E.J.; Lim, K.H. Polyelectrolyte complexes of chitosan self-assembled with fucoidan: An optimum condition to prepare their nanoparticles and their characteristics. *Korean J. Chem. Eng.* 2014, 31, 664–675. [CrossRef]

154. Lee, E.J.; Lim, K.-H. Formation of chitosan-fucoidan nanoparticles and their electrostatic interactions: Quantitative analysis. *J. Biosci. Bioeng.* 2016, 121, 73–83. [CrossRef] [PubMed]

155. Ho, T.T.M.; Bremmell, K.E.; Krasowska, M.; Stringer, D.N.; Thierry, B.; Beattie, D.A. Tuning polyelectrolyte multilayer structure by exploiting natural variation in fucoidan chemistry. *Soft Matter* 2015, 11, 2110–2124. [CrossRef] [PubMed]

156. Bachelet-Violette, L.; Silva, A.K.A.; Maire, M.; Michel, A.; Brinza, O.; Ou, P.; Ollivier, V.; Nicoletti, A.; Wilhelm, C.; Letourneur, D.; et al. Strong and specific interaction of ultra small superparamagnetic iron oxide nanoparticles and human activated platelets mediated by fucoidan coating. *RSC Adv.* 2014, 4, 4864–4871. [CrossRef]

157. Bonnard, T.; Yang, G.; Petiet, A.; Ollivier, V.; Haddad, O.; Arnaud, D.; Louedec, L.; Bachelet-Violette, L.; Derkaoui, S.M.; Letourneur, D.; et al. Abdominal Aortic Aneurysms Targeted by Functionalized Polysaccharide Microparticles: A New Tool for SPECT Imaging. *Theranostics* 2014, 4, 592–603. [CrossRef] [PubMed]
158. Rouzet, F.; Bachelet-Violette, L.; Alsac, J.M.; Suzuki, M.; Meulemans, A.; Louedec, L.; Petiet, A.; Jandrot-Perrus, M.; Chauabet, F.; Michel, J.B.; et al. Radiolabeled fucoidan as a p-selectin targeting agent for in vivo imaging of platelet-rich thrombus and endothelial activation. *J. Nucl. Med.* 2011, 52, 1433–1440. [CrossRef] [PubMed]

159. Bonnard, T.; Serfaty, J.-M.; Journé, C.; Noe, B.H.T.; Arnaud, D.; Louedec, L.; Derkaoui, S.M.; Letourner, D.; Chauvierre, C.; Le Visage, C. Leukocyte mimic polysaccharide microparticles tracked in vivo on activated endothelium and in abdominal aortic aneurysm. *Acta Biomater.* 2014, 10, 3535–3545. [CrossRef] [PubMed]

160. Nakamura, S.; Nambu, M.; Ishizuka, T.; Hattori, H.; Kanatani, Y.; Takase, B.; Kishimoto, S.; Amano, Y.; Maire, M.; Rolland, L.; et al. Purification of a Low Molecular Weight Fucoidan for SPECT Molecular Imaging of Myocardial Infarction. *Mar. Drugs* 2014, 12, 4851–4867. [CrossRef] [PubMed]

161. Sezer, A.D.; Akbüga, J. Fucosphere—New microsphere carriers for peptide and protein delivery: Preparation and in vivo characterization. *J. Microencapsul.* 2006, 23, 513–522. [CrossRef] [PubMed]

162. Nakamura, S.; Nambu, M.; Ishizuka, T.; Hattori, H.; Kanatani, Y.; Takase, B.; Kishimoto, S.; Amano, Y.; Aoki, H.; Kiyosawa, T.; et al. Effect of controlled release of fibroblast growth factor-2 from chitosan/fucoidan micro complex-hydrogel on in vitro and in vivo vascularization. *J. Biomed. Mater. Res. 2008*, 85, 619–627. [CrossRef] [PubMed]

163. Huang, Y.-C.; Yang, Y.-T. Effect of basic fibroblast growth factor released from chitosan-fucoidan nanoparticles on neurite extension. *J. Tissue Eng. Regen. Med.* 2016, 10, 418–427. [CrossRef] [PubMed]

164. Huang, Y.-C.; Liu, T.-J. Mobilization of mesenchymal stem cells by stromal cell-derived factor-1 released from chitosan/tripolyphosphate/fucoidan nanoparticles. *Acta Biomater.* 2012, 8, 1048–1056. [CrossRef] [PubMed]

165. Park, S.; Hwang, S.; Lee, J. pH-responsive hydrogels from moldable composite microparticles prepared by coaxial electro-spray drying. *Chem. Eng. J.* 2011, 169, 348–357. [CrossRef]

166. Yu, S.H.; Wu, S.J.; Wu, J.Y.; Wen, D.Y.; Mi, F.L. Preparation of fucoidan-shelled and genipin-crosslinked Yeh, T.-H.; Hsu, L.-W.; Tseng, M.T.; Lee, P.-L.; Sonjae, K.; Ho, Y.-C.; Sung, H.-W. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. *Biomaterials* 2011, 32, 6164–6173. [CrossRef] [PubMed]

167. Huang, Y.C.; Kuo, T.H. O-carboxymethyl chitosan/fucoidan nanoparticles increase cellular curcumin uptake. *Food Hydrocoll.* 2016, 53, 261–269. [CrossRef]

168. Kimura, R.; Rokkaku, T.; Takeda, S.; Senba, M.; Mori, N. Cytotoxic effects of fucoidan nanoparticles against osteosarcoma. *Mar. Drugs* 2013, 11, 4267–4278. [CrossRef] [PubMed]

169. Yeh, T.-H.; Hsu, L.-W.; Tseng, M.T.; Lee, P.-L.; Sonjae, K.; Ho, Y.-C.; Sung, H.-W. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. *Biomaterials* 2011, 32, 6164–6173. [CrossRef] [PubMed]

170. Huang, Y.C.; Lam, U.-I. Chitosan/fucoidan pH sensitive nanoparticles for oral delivery system. *J. Chin. Chem. Soc.* 2011, 58, 779–785. [CrossRef]

171. Lee, K.W.; Jeong, D.; Na, K. Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment. *Carbohydr. Polym.* 2013, 94, 850–856. [CrossRef] [PubMed]

172. Kimura, R.; Rokkaku, T.; Takeda, S.; Senba, M.; Mori, N. Cytotoxic effects of fucoidan nanoparticles against osteosarcoma. *Mar. Drugs* 2013, 11, 4267–4278. [CrossRef] [PubMed]

173. Huang, Y.C.; Lam, U.-I. Chitosan/fucoidan pH sensitive nanoparticles for oral delivery system. *J. Chin. Chem. Soc.* 2011, 58, 779–785. [CrossRef]

174. Kimura, R.; Rokkaku, T.; Takeda, S.; Senba, M.; Mori, N. Cytotoxic effects of fucoidan nanoparticles against osteosarcoma. *Mar. Drugs* 2013, 11, 4267–4278. [CrossRef] [PubMed]

175. Yu, S.H.; Tang, D.W.; Hsieh, H.Y.; Wu, W.S.; Lin, B.X.; Chuang, E.Y.; Sung, H.W.; Mi, F.L. Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers. *Acta Biomater.* 2013, 9, 7449–7459. [CrossRef] [PubMed]

176. Huang, Y.C.; Lam, U.-I. Chitosan/fucoidan pH sensitive nanoparticles for oral delivery system. *J. Chin. Chem. Soc.* 2011, 58, 779–785. [CrossRef]

177. Lee, K.W.; Jeong, D.; Na, K. Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment. *Carbohydr. Polym.* 2013, 94, 850–856. [CrossRef] [PubMed]

178. Kimura, R.; Rokkaku, T.; Takeda, S.; Senba, M.; Mori, N. Cytotoxic effects of fucoidan nanoparticles against osteosarcoma. *Mar. Drugs* 2013, 11, 4267–4278. [CrossRef] [PubMed]

179. Yu, S.H.; Tang, D.W.; Hsieh, H.Y.; Wu, W.S.; Lin, B.X.; Chuang, E.Y.; Sung, H.W.; Mi, F.L. Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers. *Acta Biomater.* 2013, 9, 7449–7459. [CrossRef] [PubMed]

180. Huang, Y.C.; Kuo, T.H. O-carboxymethyl chitosan/fucoidan nanoparticles increase cellular curcumin uptake. *Food Hydrocoll.* 2016, 53, 261–269. [CrossRef] [PubMed]

181. Wu, S.J.; Don, T.M.; Lin, C.W.; Mi, F.L. Delivery of Berberine Using Chitosan/Fucoidan-Taurine Conjugate Nanoparticles for Treatment of Defective Intestinal Epithelial Tight Junction Barrier. *Mar. Drugs* 2014, 12, 5677–5697. [CrossRef] [PubMed]

182. Kimura, R.; Rokkaku, T.; Takeda, S.; Senba, M.; Mori, N. Cytotoxic effects of fucoidan nanoparticles against osteosarcoma. *Mar. Drugs* 2013, 11, 4267–4278. [CrossRef] [PubMed]

183. Yu, S.H.; Tang, D.W.; Hsieh, H.Y.; Wu, W.S.; Lin, B.X.; Chuang, E.Y.; Sung, H.W.; Mi, F.L. Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers. *Acta Biomater.* 2013, 9, 7449–7459. [CrossRef] [PubMed]

184. Huang, Y.C.; Kuo, T.H. O-carboxymethyl chitosan/fucoidan nanoparticles increase cellular curcumin uptake. *Food Hydrocoll.* 2016, 53, 261–269. [CrossRef] [PubMed]

185. Wu, S.J.; Don, T.M.; Lin, C.W.; Mi, F.L. Delivery of Berberine Using Chitosan/Fucoidan-Taurine Conjugate Nanoparticles for Treatment of Defective Intestinal Epithelial Tight Junction Barrier. *Mar. Drugs* 2014, 12, 5677–5697. [CrossRef] [PubMed]

186. Pinheiro, A.C.; Bourbon, A.I.; Cerqueira, M.A.; Maricato, E.; Nunes, C.; Coimbra, M.A.; Vicente, A.A. Chitosan/fucoidan multilayer nanocapsules as a vehicle for controlled release of bioactive compounds. *Carbohydr. Polym.* 2015, 115, 1–9. [CrossRef] [PubMed]

187. Yeh, T.-H.; Hsu, L.-W.; Tseng, M.T.; Lee, P.-L.; Sonjae, K.; Ho, Y.-C.; Sung, H.-W. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. *Biomaterials* 2011, 32, 6164–6173. [CrossRef] [PubMed]
178. Da Silva, L.C.G.T.; Mori, M.; Sandri, G.; Bonférion, M.C.; Finotelli, P.V.; Cinelli, L.P.; Caramella, C.; Cabral, L.M. Preparation and characterization of poly saccharide-based nanoparticles with anticoagulant activity. *Int. J. Nanomed.* 2012, 7, 2975–2986. [CrossRef] [PubMed]

179. Sezer, A.D.; Akbüz, J. Comparison on in vitro characterization of fucospheres and chitosan microspheres encapsulated plasmid DNA (pGM-CSF): Formulation design and release characteristics. *AAPS PharmSciTech* 2009, 10, 1193–1199. [CrossRef] [PubMed]

180. Kurosaki, T.; Kitahara, T.; Kawakami, S.; Nishida, K.; Nakamura, J.; Teshima, M.; Nakagawa, H.; Kodama, Y.; To, H.; Sasaki, H. The development of a gene vector electrostatically assembled with a polysaccharide capsule. *Biomaterials* 2009, 30, 4427–4434. [CrossRef] [PubMed]

181. Venkatesan, J.; Bhatnagar, I.; Kim, S.K. Chitosan-alginate biocomposite containing fucoidan for bone tissue engineering. *Mar. Drugs* 2014, 12, 300–316. [CrossRef] [PubMed]

182. Jeong, H.S.; Venkatesan, J.; Kim, S.K. Hyaluronic acid–fucoidan nanocomposites for bone tissue engineering. *Int. J. Biol. Macromol.* 2013, 57, 138–41. [CrossRef] [PubMed]

183. Lowe, B.; Venkatesan, J.; Anil, S.; Shim, M.S.; Kim, S.K. Preparation and characterization of chitosan-natural nano hyaluronic acid–fucoidan nanocomposites for bone tissue engineering. *Int. J. Biol. Macromol.* 2016. [CrossRef] [PubMed]

184. Puvaneswary, S.; Talebian, S.; Raghavendran, H.B.; Murali, M.R.; Mehrizi, M.; Afifi, A.M.; Kasim, N.H.; Kamarul, T. Fabrication and in vitro biological activity of betaTCP-Chitosan-Fucoidan composite for bone tissue engineering. *Carbohydr. Polym.* 2015, 134, 799–807. [CrossRef] [PubMed]

185. Changotade, S.I.; Korb, G.; Bassil, J.; Barroukh, B.; Willig, C.; Colliec-Jouault, S.; Durand, P.; Godeau, G.; Senni, K. Potential effects of a low-molecular-weight fucoidan extracted from brown algae on bone biomaterial osteoconductive properties. *J. Biomed. Mater. Res. A* 2008, 87, 666–675. [CrossRef] [PubMed]

186. Jin, G.; Kim, G.H. Rapid-prototyped PCL/fucoidan composite scaffolds for bone tissue regeneration: Design, fabrication, and physical/biological properties. *J. Mater. Chem.* 2011, 21, 17710–17718. [CrossRef] [PubMed]

187. Lee, J.S.; Jin, G.H.; Yeo, M.G.; Jang, C.H.; Lee, H.; Kim, G.H. Fabrication of electrospun biocomposites comprising polycaprolactone/fucoidan for tissue regeneration. *Carbohydr. Polym.* 2012, 90, 181–188. [CrossRef] [PubMed]

188. Lira, M.C.; Santos-Magalhaes, N.S.; Nicolas, V.; Marsaud, V.; Silva, M.P.; Ponchel, G.; Vauthier, C. Cytotoxicity and cellular uptake of newly synthesized fucoidan-coated nanoparticles. *Eur. J. Pharm. Biopharm.* 2011, 79, 162–70. [CrossRef] [PubMed]

189. Sezer, A.D.; Cevher, E.; Hatipoglu, F.; Oğurtan, Z.; Baş, A.L.; Akbuğa, J. The use of fucosphere in the treatment of dermal burns in rabbits. *Eur. J. Pharm. Biopharm.* 2008, 69, 189–198. [CrossRef] [PubMed]

190. Sezer, A.D.; Cevher, E.; Hatipoglu, F.; Oğurtan, Z.; Bas, A.L.; Akbuğa, J. Preparation of fucoidan-chitosan hydrogel and its application as burn healing accelerator on rabbits. *Biol. Pharm. Bull.* 2008, 31, 2326–2333. [CrossRef] [PubMed]

191. Suzuki, M.; Bachelet-Violette, L.; Rouzet, F.; Beilvert, A.; Autret, G.; Maire, M.; Menager, C.; Louedec, L.; Chouqueux, C.; Saboural, P.; et al. Ultrasmall superparamagnetic iron oxide nanoparticles coated with fucoidan for molecular MRI of intraluminal thrombus. *Nanomedicine* 2015, 10, 73–87. [CrossRef] [PubMed]

192. Senni, K.; Pereira, J.; Gueniche, F.; Delbarre-Ladrat, C.; Sinquin, C.; Ratiskol, J.; Godeau, G.; Fischer, A.M.; Helley, D.; Colliec-Jouault, S. Marine polysaccharides: A source of bioactive molecules for cell therapy and tissue engineering. *Mar. Drugs* 2011, 9, 1664–1681. [CrossRef] [PubMed]

193. Ermakova, S.; Kusaykin, M.; Trincione, A.; Tatiana, Z. Are multifunctional marine polysaccharides a myth or reality? *Front. Chem.* 2015, 3, 39. [CrossRef] [PubMed]

194. Seeberger, P.H.; Create, D.B. Synthesis and medical applications of oligosaccharides. *Nature* 2007, 446, 1046–1051. [CrossRef] [PubMed]

195. Linhardt, R.J.; Gunay, N.S. Production and chemical processing of low molecular weight heparins. *Semin. Thromb. Hemost.* 1999, 25, 5–16. [PubMed]

196. Chavaroche, A.A.; van den Broek, L.A.; Eggink, G. Production methods for heparosan, a precursor of heparin and heparan sulfate. *Carbohydr. Polym.* 2013, 93, 38–47. [CrossRef] [PubMed]

197. Gray, E.; Mulloy, B.; Barrowcliffe, T.W. Heparin and low-molecular-weight heparin. *Thromb. Haemost.* 2008, 99, 807–818. [CrossRef] [PubMed]

198. Kakkar, V.V.; Djazaeri, B.; Fok, J.; Fletcher, M.; Scully, M.F.; Westwick, J. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. *Br. Med. J.* 1982, 284, 375–379. [CrossRef]
199. Liu, H.; Zhang, Z.; Linhardt, R.J. Lessons learned from the contamination of heparin. *Nat. Prod. Rep.* 2009, 26, 313–321. [CrossRef] [PubMed]

200. Doshi, N.; Mitragotri, S. Designer Biomaterials for Nanomedicine. *Adv. Funct. Mater.* 2009, 19, 3843–3854. [CrossRef]

201. Gupta, A.S. Nanomedicine approaches in vascular disease: A review. *Nanomedicine* 2011, 7, 763–779. [CrossRef] [PubMed]

202. Sainz, V.; Conniot, J.; Matos, A.I.; Peres, C.; Zupancic, E.; Moura, L.; Silva, L.C.; Florindo, H.F.; Gaspar, R.S. Regulatory aspects on nanomedicines. *Biochem. Biophys. Res. Comm.* 2015, 468, 504–510. [CrossRef] [PubMed]

203. Chauvierre, C.; Letourneur, D. The European project NanoAthero to fight cardiovascular diseases using nanotechnologies. *Nanomedicine* 2015, 10, 3391–3400. [CrossRef] [PubMed]